Guttify, the premium gut health startup by Lifechart, is in advanced negotiations with leading venture capital firms to secure Rs 20 crore in its upcoming funding round. The company, recognised for its “Diagnosis-First” approach to gut wellness, has rapidly gained traction in the consumer healthcare space. Sources indicate that 60 per cent of the round is expected to close with a prominent VC specialising in healthcare and consumer investments. Guttify’s credibility is further bolstered by the recent addition of Prashant Pitti (Founder, EaseMyTrip & Optimio) as a strategic advisor and investor, along with support from UNICHEM Laboratories' family office and existing backers. In May 2025, the startup raised USD 360,000 in extended seed funding, bringing its total funding to over USD 1 million. The fresh capital will fuel Guttify’s expansion of its diagnosis-first, at-home gut wellness solutions across urban and semi-urban India. "Our mission is to solve chronic gut health issues from the core using science and diagnostics. The new funding will help us scale product development, distribution, and research for personalised gut care," said Mukul Shah, co-founder at Guttify. As part of its innovation pipeline, Guttify is set to launch India’s first RNA gene-based DIY gut testing kits, promising results within 24 hours. This affordable, at-home solution aims to democratise gut health testing, enabling individuals to better understand and manage their digestive health without invasive procedures or clinic visits. Source: bwhealthcareworld #healthcarestartupindia #dseidehealthcarenetwork

Suraksha Diagnostic Limited (Suraksha Daignostic), one of the leading diagnostics chains in Eastern India has launched one of the largest and a state-of-the-art genomics labs in Eastern India. The launch was graced by Prof. Sukumar Mukherjee, a distinguished rheumatologist with more than 35 years of extensive experience in the field and a mentor at Suraksha Diagnostic. The global genetic testing market is valued at USD 38.77 billion (2024) and is projected to reach US$ 186.64 billion by the year 2035 (CAGR: 22.5%). In a landmark move, Suraksha Diagnostic has invested ₹22 crores in establishing its Genomics Lab. An additional Rs. 46 crore investment is planned over the next 24 months to establish one of Asia's most advanced Genomics Laboratories. This initiative is a significant leap forward for West Bengal, Eastern & North-Eastern India, and India's future in precision diagnostics. This Lab is equipped with Cytogenetics, Microarray Technology, Sanger Sequencing, Multiple Next-Generation Sequencers (NGS). Together, these technologies enable the full spectrum of advanced genetic testing, offering predictive, preventive, and personalized care. Speaking on the launch of the genomics lab, Dr. Somnath Chatterjee, Chairman & Joint Managing Director, Suraksha Diagnostic, said: "A huge transformation is sweeping across medicine today. At the heart of this revolution lies Genomics - unlocking the secrets of the Human Genome, enabling early diagnosis, predictive analytics, and personalized treatments. From Fetal Medicine to Oncology and Rare Diseases, genomic science is rewriting the future of healthcare. Suraksha Diagnostic is proud to be at the forefront of this revolution." Ritu Mittal, Joint Managing Director & CEO, Suraksha Diagnostic, also emphasized the lab's role in making genomic diagnostics a critical part of healthcare decision- making in Eastern India and shared: "We provide end-to-end solution for prenatal genetics, offering comprehensive testing facilities. We aim to be a premium, aspirational choice for clinicians and families seeking the highest standards in fetal, reproductive, paediatric and onco-genetics without the need to send samples out of the region or compromise on quality Source: Indian Pharma Post #healthcarstartupindia #dseidehealthcarenetwork

Mumbai-based fertility health-tech startup Luma Fertility has raised $4 million in seed funding, led by Peak XV’s Surge, with participation from Ameera Shah (Metropolis Healthcare) and Vijay Taparia (B2V Ventures). The funding will help Luma expand its footprint in Mumbai and later scale into subsequent cities over the next two years. Ameera Shah, promoter and executive chairperson of Metropolis Healthcare, said, “Fertility care in India is at an inflection point. Demand is growing rapidly, but the system is deeply fragmented and outdated. Patients are forced to navigate a maze of clinics, labs, and specialists with little coordination or support.” Founded by Neha K. Motwani, Luma Fertility’s 6,000-square-foot facility houses a lab and offers comprehensive in-house fertility procedures. Its services include IVF, egg and embryo freezing, fertility assessments, and pre-conception consultations. Luma also offers at-home semen analysis, personalised reports, and a range of holistic services—such as nutrition guidance, acupuncture, IV drips, and one-on-one sessions—to support both physical and emotional well-being and improve overall outcomes. Luma is the first IVF clinic to launch an integrated app, allowing patients to track their treatment, access reports, and stay informed. Its AI-enabled tool, LumaAI, offers 24/7, jargon-free support on everything from cycle timelines to medication guidance. The global fertility services market is projected to reach $53 billion by 2030, driven by factors such as delayed parenthood, increasing age-related infertility, and declining global fertility rates. In India, the total fertility rate is at a historic low, declining from 2.1 to 1.9 births per woman. Over 33 million couples in the country face fertility challenges, with IVF cycles expected to grow from 320,000 in 2024 to 550,000 by 2028. As India’s economy evolves and per capita income rises, there is significant latent demand for transparent, patient-centric, and tech-enabled fertility solutions, including egg and embryo freezing. Source: Business Standard #healthtechstartup #dseidehealthcarenetwork

GTT Data Solutions has unveiled GAIN (GTT Data AI Accelerator Network)—a strategic initiative designed to accelerate India’s AI startup ecosystem by fostering innovation, collaboration, and funding support. The accelerator will provide mentorship, business advisory services, go‑to‑market assistance, and access to strategic partnerships across sectors such as healthcare, pharmaceuticals, engineering, retail, legal, and real estate  GAIN aims to support more than 100 AI startups over the next six months, with potential investments facilitated through Sangli Miraj Commercial Ventures The launch event in Pune featured 22 AI companies and 45 founders showcasing innovations centered on intelligent automation, advanced healthcare AI (including medical imaging), and vision AI focused on visual data processing GTT Data’s President, Srikumar Kumar, emphasized a philosophy of “dual intelligence”—where AI complements human expertise—and emphasized that AI must uplift humans, not replace them. He added, “GAIN is our commitment to making India a formidable, collaborative force in the global AI movement”  This initiative addresses critical challenges facing India's AI startup landscape, which now hosts over 4,500 ventures, nearly 40% of which were founded in the past three years. With a steep failure rate—90% don't survive, and 70% shut down within a decade—GAIN seeks to foster collaboration over competition and support startups in building scalable, sustainable business models  Why this matters: Bridging the gap between early‑stage AI innovation and real‑world adoption. Enhancing survival prospects for startups by offering funding access, mentorship, and market entry support. Targeting critical AI verticals like healthcare imaging and cognitive automation—key growth drivers. Backing from established players, ensuring credibility and expanded ecosystem connectivity. With GAIN, GTT Data is taking a proactive step in nurturing India’s deep‑tech future, reinforcing its broader ambition to scale its Dual Intelligence strategy through acquisitions, talent development, and expanded operations across tier‑2 and tier‑3 cities  Source: Times of India #healthcarestartupindia #dseidehealthcarenetwork

As healthcare costs continue to rise and insurance penetration remains limited—currently covering only about 36% of the population—millions of Indians are left financially vulnerable during medical emergencies. Recognising this systemic gap, fintech innovator CarePay has launched Careena – an AI-powered healthcare EMI platform designed to make medical financing more seamless, accessible, and patient-centric across India. CarePay’s newly launched platform offers instant, no-cost EMI approvals up to ₹10 lakhs for a wide spectrum of healthcare needs, including surgeries, diagnostics, chronic disease management, and preventive health services. At the heart of this digital transformation is Careena (CARE Engagement Assistant), an intelligent AI-based assistant developed to guide patients through the financing process in real-time. Built with user-centricity in mind, Careena evaluates key data points such as employment status, educational background, and income levels to offer instant eligibility checks and approval decisions within minutes—a process that traditionally took days. “Our goal is to dismantle the financial barriers preventing timely medical intervention. Careena is more than just a digital tool—it’s a healthcare financing companion that ensures timely access to quality care without the financial stress,” said Gaurav Gupta, CEO of CarePay. Key features of the platform include: 0% EMI options, where partnering hospitals absorb the interest cost to enhance patient acquisition. AI-based risk assessment that ensures accurate and swift loan approvals. Mobile-first design for easy access across all devices and seamless integration with hospital management systems. End-to-end encryption and regulatory compliance to uphold data privacy and security. The company has already gained significant traction in the healthcare ecosystem, with strategic alliances across 550+ wellness centres, 1,500+ clinics, and over 30 leading hospitals. CarePay has also collaborated with five multinational healthcare firms and 25 chronic care facilities to broaden the reach of its innovative financial solutions. Source: e.health #healthcarestartupinindia #dseidehealthcarenetwork

Over the past week, you might’ve noticed something interesting. Shares of India’s diagnostic companies have taken a bit of a tumble. Stocks like Suraksha Diagnostic, Krsnaa Diagnostics, Thyrocare Technologies, Metropolis and Dr. Lal PathLabs slipped by up to 2%, even as the broader market moved in the opposite direction. And you’ve probably guessed what’s spooked investors this time. But if you haven’t, well, Amazon just threw its hat into India’s diagnostics ring. It’s now offering at-home test collections, digital reports and bundled health services across six cities covering 450 pincodes. The buzz is that it could shake things up in a big way. But here’s the thing. This isn’t Amazon’s first rodeo in Indian healthcare. It’s already dipped its toes into e-pharmacies and online consultations. Sure, those services are still around, but let’s be honest. They haven’t exactly set the world on fire. It’s more of a work-in-progress than a roaring success. So why is Amazon doubling down and adding new pieces to its healthcare puzzle when it hasn’t really cracked the code yet? Well, the simplest answer is that it already had e-pharmacies. But to figure out what to sell, it needed to know why people were buying medicines in the first place. That’s where online consultations came in handy. People could talk to doctors from home, get prescriptions and Amazon could plug into that system — supplying medicines and figuring out which pharmacy partners to work with in each region. But what happens when a doctor suggests a blood test? People typically head to the nearest lab or get it done through a hospital. That’s a piece of the puzzle Amazon didn’t have. So diagnostics felt like a natural extension. And when you zoom out, the diagnostics space in India does look like a ripe opportunity. For context, right now, hospital labs control about 38% of the market. Standalone diagnostic centres take 37% and the big branded chains — the likes of Dr. Lal PathLabs and Thyrocare, hold the remaining 22%. But rewind to five years ago, and the picture looked different. Back then, standalone labs dominated nearly half the market, while big chains held just a measly 15%. Clearly, the winds have shifted. Source: finshots.in #healthcarestartup #dseidehealthcarenetwork

Dr. Lal PathLabs Limited (DLPL), one of India’s leading diagnostic chains, has significantly enhanced its genomics capabilities by integrating Illumina’s NovaSeq X Series into its dedicated genomics arm, Genevolve. State-of-the-art sequencing technology The NovaSeq X system uses Illumina’s breakthrough XLEAP‑SBS chemistry. With high throughput, outstanding accuracy, and energy-efficient design, it can sequence over 20,000 whole human genomes per year—more than twice the capacity of previous Illumina models. Boosting speed and precision This integration enables DLPL to deliver faster turnaround times and greater sequencing depth—critical for precise, AI-powered healthcare insights. Enabling large-scale genomic research in India From population genomics to rare disease detection and personalized medicine, this deployment accelerates India’s journey toward wide-scale genomics-based healthcare solutions. SOURCE- ECONOMICS TIME

In his 123rd episode of “Mann Ki Baat” on June 29, 2025, Prime Minister Narendra Modi underscored the profound link between India’s heritage and public health. He emphasized the value of yoga for both physical and mental wellness, encouraging daily practice as a vital habit. He also noted that religious pilgrimages reinforce cultural well-being and foster social cohesion. A major announcement during the broadcast was that India has been declared Trachoma-free, marking a significant milestone in eradicating preventable diseases nationwide. Further, PM Modi reiterated that Ayurveda goes beyond treating illness—it promotes a holistic way of life, rooted in the ancient Indian philosophy of Vasudhaiva Kutumbakam (“the world is one family”). He highlighted India’s leading role in traditional medicine through initiatives like the WHO Global Centre for Traditional Medicine and India’s global promotion of wellness systems. He also emphasized the importance of technology in healthcare, noting the adoption of digital health IDs, telemedicine, and AI-driven monitoring of maternal and child health—citing over 340 million tele-consultations via India’s free telehealth services. timesofindia.indiatimes.com ✅ Key Takeaways: Yoga & Ayurveda: Central tools in promoting physical, mental, and societal well-being, with global acceptance through International Yoga Day and traditional medicine summits. Public Health Milestone: Declaration of India as Trachoma-free reflects national success in disease prevention. Digital Healthcare Integration: Use of advanced technologies and telemedicine to improve healthcare access across India. Source: ddnews.gov.in #healthcarestartupnews #dseidehealthcarenetwork

Star Health and Allied Insurance Company Ltd. (Star Health) India's largest retail health insurer, has entered into a strategic partnership with Medi Assist Healthcare Services Limited (Medi Assist), to adopt MAtrix platform, an advanced AI-powered claims platform. This collaboration is a significant step in Star Health's ongoing claims transformation journey, focused on delivering faster settlements, better customer engagement, and technology-led service excellence. The partnership will help in identification and elimination of fraud and reduction in waste and abuse through AI tools. Through the partnership Star Health Insurance is modernising its claims ecosystem to be future-ready. The platform will help the Company strengthen its ability to manage rising claim volumes while maintaining speed, consistency, and transparency in its operations. As part of this transformation, Star Health Insurance is scaling up its digital capabilities to meet growing service expectations from hospitals, policyholders and regulators. The use of the platform introduces intelligent automation, reduces manual steps, and streamlines workflows, enabling stronger turnaround performance across the network. Anand Roy, MD & CEO, Star Health and Allied Insurance said, "This marks a major step forward in strengthening our in-house claim management capabilities. This partnership is a key milestone in our journey to build a more agile and technology-driven claims ecosystem. Claims are at the heart of the insurance experience, and with Medi Assist's platform, we are enhancing speed, accuracy, and consistency, while keeping a keen eye on fraud, waste and abuse. By reducing manual interventions and standardising processes, we aim to strengthen efficiency and reinforce trust with our policyholders. This along with other initiatives being undertaken at Star Health Insurance will ensure our focus remains on delivering transparent, reliable, and customer-first claims service that meets the evolving needs of the health insurance and healthcare landscape." Echoing this sentiment, Satish Gidugu, CEO, Medi Assist said, "We are excited to collaborate on this transformative journey. This partnership is set to redefine industry standards in technology-driven insurance operations, ensuring an exceptional Policyholder experience." This integration represents a critical advancement in India's digital health insurance landscape combining innovation, operational readiness, and a sharper focus on policyholder outcomes. Source: indianpharmapost #healthcarestartup #starthealthinsurance #dseidehealthcarenetwork

Healthtech HR platform Jobizo has raised Rs 12 crore in a pre-Series A funding round led by Inflection Point Ventures, a Gurugram-based angel investment firm, along with Alkemi Ventures. The startup will use the raised funds to accelerate product innovation, scale marketing efforts, bolster team strength, and support working capital needs. Founded in December 2021 by Naveen Trehan and Avishek Agarwal, Jobizo said it is focused on addressing critical gaps in healthcare staffing from urgent short-term hiring and undertrained professionals to system-wide inefficiencies. Its online platform leverages smart technology to connect healthcare institutions with pre-verified professionals for both temporary and permanent roles. According to the startup, Jobizo has facilitated more than 18,500 temporary job placements and over 875 permanent hires across India. It has also supported over 1,000 international placements and maintains a verified pool of more than 60,000 healthcare professionals. "This round gives us the fuel to deepen our technology stack and expand across both domestic and international markets," says Avishek Agarwal, who is also the CEO of the company. "We are laser-focused on bridging the global healthcare skills gap while offering flexible, meaningful job opportunities. Strengthening our core team and launching in more cities will be a key part of our growth roadmap." Jobizo differentiates itself through its AI-enabled, real-time job-matching technology, which it claims enables faster and more precise placement of healthcare professionals. The platform currently offers coverage across India, including locum roles in Delhi NCR and Bengaluru, as well as permanent positions in multiple cities. Internationally, Jobizo operates a recruitment network spanning more than 41 countries, including the United Arab Emirates, South Africa, Kenya, and Nepal. The Indian healthcare hiring market is projected to reach $6.38–$12.76 billion by 2030, driven by rising demand, government reforms, and private investments. Globally, the market is poised to hit $62–$65 billion, fueled by aging populations, chronic disease burdens, and structural healthcare reforms. Vinay Bansal, Founder, Inflection Point Ventures, said, “Healthcare is an extremely important segment, and at the heart of it are people. Hence, it goes without saying, how crucial it is that the right people are hired for the job. However, the hiring process tends to be long, arduous and unreliable. Currently, healthcare is facing a major manpower crunch. It is reflected in the shortage and mismatch of healthcare talent. Jobizo is bridging the gap between healthcare and qualified professionals by making hiring faster, more flexible and digital thus solving multiple pain points across the healthcare employment ecosystem.” Source: indian startup news #healthcarestartupinindia #dseidehealthcarenetwork

Medicine is undergoing a profound transformation, driven by rapid technological advances. From AI and telemedicine to wearables and genomics, digital tools are redefining how doctors diagnose, treat, and prevent disease. What began as a pandemic-fueled pivot is now a permanent shift toward smarter, more connected, and personalised healthcare. To help understand how digital innovation is shaping the future of medicine, Ayush Chauhan, Executive Director of Prakash Hospital, Noida, shared his insights. Artificial intelligence is probably the most powerful force reshaping medicine today. From reading radiology images to predicting patient outcomes, AI technologies are improving accuracy and reducing human error. Chauhan explains, “AI programs can detect breast cancer in mammograms with 94.5% accuracy, matching or even surpassing that of human radiologists. AI is also hastening the discovery of drugs. SOURCE- NEWS 18

Harpreet Singh Rai, who led Oura Ring from under $1 million to a $200 million revenue run‑rate, has been appointed President of Healthcare at Y Combinator‑backed Loop Health . This move marks Rai's return to full‑time startup leadership after leaving Oura in late 2021. Based between the US and India, he will oversee Loop's entire healthcare stack—including product, telehealth, diagnostics, and clinical services—and spend about half his time in India . Rai described India’s healthcare sector as undergoing a “UPI moment,” indicating a pivotal point in scaling digital-first, employer-led care innovations . His appointment aligns with Loop Health’s ambition to evolve from a B2B insurance provider into a comprehensive preventive healthcare platform. The startup, founded in 2018 and backed by investors like Elevation Capital and General Catalyst, has raised approximately $41 million to date . Source: moneycontrol.com #healthtechstartupindia #dseidehealthcarenetwork

At FutureMed X, thought leaders, healthcare innovators, and data scientists came together to redefine what tomorrow’s healthcare could look like. The discussions centered on creating a system that is: ✅ Intelligent – Leveraging AI, machine learning, and predictive analytics to personalize treatment and improve diagnostics. ✅ Inclusive – Ensuring equitable access to healthcare across geography, gender, age, and socio-economic strata. ✅ Data-Driven – Using real-time, interoperable data to guide clinical decisions, public health strategies, and medical research. 📊 Key Takeaways: – AI is transforming early diagnosis and predictive care – Digital health tools are bridging the urban-rural healthcare gap – Data interoperability is essential for collaborative, patient-centered care – Inclusion means building tech that’s accessible and culturally sensitive This blueprint isn’t just visionary—it’s actionable. The convergence of tech, policy, and human-centered design is paving the way for a healthier, more connected world. SOURCE- Health World (Economic Times) #FutureMedX #DigitalHealth #AIinHealthcare #HealthEquity #DataDrivenHealth #SmartHealthcare #InclusiveHealth #HealthTech #MedTechInnovation #PrecisionMedicine #HealthcareTransformation #Interoperability #HealthPolicy #HealthInnovation #PatientCentricCare

AI is helping doctors in India detect cancer early, even before symptoms appear by spotting hidden signs in routine tests, expanding access in rural areas, and supporting faster, life-saving decisions. Imagine going for a routine health check-up, just your regular blood tests and a chest X-ray. You feel completely fine. No pain, no symptoms. But a few days later, your doctor calls with unexpected news. An AI tool has picked up something unusual. After more tests, it turned out to be a small cancerous growth which was caught early, before it could spread or cause any symptoms. This may sound like something from the future, but it’s already happening in India and around the world. Artificial Intelligence, or AI, is changing how doctors find cancer by spotting warning signs early, even when the patient feels perfectly healthy. And this shift couldn’t come at a better time. SOURCE- Financialexpress #AIinHealthcare #MedicalAI #DigitalHealth #HealthTech #SmartHealthcare #MedTech #FutureOfMedicine

Indian medical tourism platform Vaidam Health has acquired MediJourney, a digital-first international patient facilitation startup incubated by Ferns N Petals (FNP) in 2024. The deal, an all-cash transaction, marks a significant consolidation in India’s burgeoning cross-border healthcare ecosystem. MediJourney, launched last year, enables international patients to connect with verified hospitals and treatment providers using a tech-enabled matchmaking interface. The acquisition will allow Vaidam Health to integrate MediJourney’s proprietary digital infrastructure into its platform, advancing its capabilities in patient onboarding, AI-assisted navigation, and multilingual case coordination. “We welcome MediJourney to Vaidam Health,” said Pankaj Chandna, Co-Founder of Vaidam Health. “MediJourney’s platform complements our infrastructure and broadens our ability to connect international patients with trusted healthcare options in India. This acquisition reflects our commitment to simplifying access to quality treatment for patients worldwide.” Founded in 2016 by Chandna and Manish Chandra, Vaidam Health facilitates over 25,000 monthly patient interactions and has an operational footprint spanning seven countries. The company provides a suite of services for medical travelers—including treatment discovery, visa facilitation, interpreter support, and post-care engagement—with a strong network of partner hospitals across India. MediJourney will continue to operate independently under Vaidam’s ownership, with its core team focusing on new strategic opportunities. Rishabh Jalan, Co-Founder of MediJourney, said, “This acquisition represents a powerful synergy between two companies that share a common vision for innovation and customer-centric solutions. By joining forces with Vaidam Health, we are ensuring that our technology and expertise reach new heights, benefiting a wider audience while allowing us to focus on new strategic opportunities.” The acquisition is projected to result in a 40 to 50% increase in active patient engagements over the next year, supported by Vaidam’s existing presence in international markets. The company plans to double down on its in-country teams and information centers in Africa and Southeast Asia to meet rising demand. Source : indian startup news #healthcarestartupindia #dseidehealthcarenetwork

Shobhana Kamineni highlights how AI—through smart devices and GenAI tools—can address doctor shortages, boost diagnostics, remote consultations, workflow efficiency, and scale care across India. She emphasizes ethical deployment, India-specific data, and public–private collaboration. 📌 Key Highlights: 1. AI is enabling Apollo’s 7,000 doctors to increase productivity by 50–85% 2. Real-time alerts, remote diagnostics, and decision-support tools are already in daily use 3. National AI-health data infrastructure, patient privacy, and representative datasets are vital #AIinHealthcare #DigitalHealth #GenAI #ApolloHospitals #AIforIndia #EthicalAI #HealthTech #PublicPrivatePartnership #SmartHealthcare

Pristyn Care has ramped up its hospital expansion strategy with the launch of three new digitally integrated hospitals in Gurgaon, Hyderabad, and Kochi, bringing its total number of owned facilities to eight, just four months after opening its first. This move also marks the startup’s entry into South India. Pristyn Care now operates a clinical footprint of 200,000 sq ft, comprising 400 beds, more than 20 modular operating theatres, over 50 ICU beds, and a team of over 550 medical professionals. The latest launch follows the company’s earlier announcement in February 2025, when it unveiled its first five hospitals within a span of just 75 days. That rapid rollout, focused around Delhi-NCR, was a significant pivot from Pristyn’s earlier asset-light model of partnering with hospitals to offering in-house surgical care. Now, with the addition of 90,000 sq ft across three cities, Pristyn is doubling down on its promise of accessible, seamless healthcare. Each new facility is being integrated with the company’s proprietary digital platform, which includes real-time clinical alerts, EMRs, express discharge tooling, and one-tap insurance approvals. “We are not starting from scratch; the technology is built and live. Our next task is to stitch it into each new hospital so patients experience shorter waits, clearer communication, and truly joined-up care, said Dr Vaibhav Kapoor, Co-founder of Pristyn Care. Pristyn Care’s new hospitals bring tailored services to each city, Gurgaon boosts neonatal and women’s health, marking its sixth facility in NCR; Hyderabad offers 24×7 trauma care and tech-led joint replacements; and Kochi adds emergency care with a riverside rehab wing for Kerala patients. Notably, Pristyn Care’s first hospital in Delhi hit double-digit profitability within eight weeks. With the strong performance metrics, the company is now targeting 50 hospitals by FY28, with upcoming launches in Mumbai, Bengaluru, and Pune. Source: Medical Buyer #healthcarestartupindia #dseidehealthcarenetwork

Amazon India customers can now book diagnostic tests on their app, as the e-commerce giant expands its medical offerings beyond online pharmacy and teleconsultations. The company sees a massive opportunity to scale up its healthcare offerings, especially in India, a senior executive said in an interview. “Healthcare is a daily need - second only to grocery in some ways. We’re not setting a fixed number goal, but this could become a very large and meaningful part of Amazon’s offerings in India,” Jayaramakrishnan Balasubramanian, category leader at Amazon Medical said. Amazon is partnering with diagnostics lab Orange Health to offer the service, beginning with Bengaluru, Delhi, Gurgaon, Noida, Mumbai and Hyderabad. The service will be scaled up gradually. SOURCE- Mint

🧠 FutureMed X: Decoding the Digital Pulse of Indian Healthcare India's healthcare landscape is evolving faster than ever — driven by innovation, necessity, and a bold digital shift. FutureMed X dives deep into this transformation, unpacking how AI, IoT, digital health records, remote care, and predictive analytics are redefining how care is delivered, experienced, and scaled in India. From bustling metro hospitals to tier-2 clinics and telehealth platforms reaching rural India, technology is no longer optional — it's essential. With this wave of transformation comes a new generation of startups, digital-first hospitals, empowered doctors, and informed patients. This series (or campaign/event) aims to: 1. Decode India’s digital healthcare journey, one trend at a time 2. Highlight real-world innovations solving deep-rooted systemic issues 3. Explore the role of platforms, data, and devices in future-ready care 4. Feature voices of healthcare leaders, technologists, policy-makers, and young innovators shaping this movement SOURCE- Health Economictimes #FutureMedX #DigitalPulseIndia #HealthTechIndia #HealthcareInnovation #AIinMedicine #TelemedicineIndia #SmartHospitals #DseideVoices #MedTechRevolution #ConnectedCare #HealthcareStartups

Often, many of us don’t get a doctor consultation for minor medical issues as doctors often don’t do home visits. Gurugram-based Kyno Health is solving for that. Founded in 2023 by Aditya Gupta, who previously worked at Pristyn Care, Kyno Health is a hyperlocal healthtech startup that offers quick general physician home visits for acute, non-emergency cases. The startup enables patients to book a home visit from a certified physician who can arrive in around 20 minutes. Over the past two years, the company says it has completed over 23,000 consultations, maintained an average travel time of 25 minutes, and achieved a 91% patient satisfaction rate. “We’re focused on creating a new category in primary care. While others serve chronic care or post-hospitalisation needs, we’re targeting real-time acute use cases—things like high-grade fever, sudden BP fluctuations, or gastric issues—that need attention within the hour but don’t warrant an ER visit,” the founder tells YourStory. How does it work? Kyno Health’s doctors—all with MBBS degrees and at least five years of experience—arrive at the patient’s home with a nurse, diagnostic support (if needed), and basic medicines in hand. Each consultation lasts 25-30 minutes, notably higher than India’s average of 4-5 minutes per consultation. “We’re trying to fix the foundation. The quality of diagnosis and medical outcomes improves when time is invested in the consultation. A rushed diagnosis often leads to overprescription or misuse of antibiotics,” he adds. Currently accessible via a web app, the startup has kept its service flow simple: users enter three basic details (name/age, symptoms, location), get an estimated time of arrival, make the payment, and are then assigned a doctor whom they can track live via the platform. Doctors, meanwhile, get alerts on their app and have cabs that are ready for dispatch. The startup partners with multiple vendors, including ZiT, Carzonrent, and WTI, for hiring cabs. Post-consultation, for medicines or nursing procedures, Kyno Health has an in-house nursing team of 38 doctors and 20 nursing staff who provide essential services. Medicines and diagnostics are offered through third-party vendors, including Portea and Health Care at Home. It also has a dedicated corporate team of 7-8 members who ensure seamless coordination for the patient. While the startup doesn’t yet provide medicine-only delivery, doctors carry all basic and emergency medicines during home visits. The system also maintains patient records securely on the backend. Doctors can view past prescriptions and visit notes through the internal app. Patients receive their handwritten prescriptions for now. A digital Electronic Medical Record (EMR) feature is in development, with the goal of building a voice-led EMR too. Source: Your story #healthcarestartupstory #dseidehealthcarenetwork

With stocks of over two lakh doses of the Hepatitis B vaccine, the Karnataka Health Department is all set to roll out a drive to vaccinate all healthcare workers against the viral infection that causes inflammation in the liver. The drive, being taken up under the National Viral Hepatitis Control Programme (NVHCP), will cover over 56,000 healthcare workers who have reasonably anticipated risks for exposure to infectious materials, including blood or bodily fluids, contaminated medical supplies and equipment, or contaminated environmental surfaces, said a senior official in charge of the programme. According to a circular issued by the State Deputy Director (NVHCP) in this regard on Wednesday, June 18, each healthcare worker will be administered three doses of the intramuscular injection into the upper arm at a gap of one month and six months respectively after the first dose. Hepatitis B vaccine stocks have been supplied by the central division to the state vaccine warehouse in Bengaluru. The stocks are now being dispatched to the district drug warehouses as per the requirement. The vaccine should be administered to all health workers (medical and paramedical staff) working in the sub-centre, primary, and community health centres, and taluk and district hospitals of the respective district, the circular stated. The vaccine supplied to the district drug warehouses should be in coordination with the Reproductive and Child Health (RCH) officers to understand the requirement under the routine immunisation programme. The District Tuberculosis Control Officers should take action in supplying the vaccine and administering it to the eligible beneficiaries. The report of vaccination to the beneficiaries should be entered in the NVHCP/MIS portal, and the staff will soon be trained on administering the vaccine and reporting, the circular added. SOURCE- THE HINDU

Miltenyi Biotec India Pvt. Ltd. and the Biotechnology Industry Research Assistance Council (BIRAC) have entered into a strategic Letter of Intent (LoI). The collaboration, formalised during the ongoing BIO International Convention 2025 in Boston, reflects a shared vision to enhance indigenous capabilities in next-generation therapeutics. The agreement outlines a multifaceted roadmap to advance India’s CGT capabilities, ranging from workforce training and translational research to point-of-care (PoC) CAR-T manufacturing and startup mentorship. This partnership is expected to play a pivotal role in transforming India into a global centre of excellence in advanced therapies. As part of the ceremonial occasion, Miltenyi Biotec India had the distinction of inaugurating the India Pavilion alongside senior dignitaries from BIRAC and the Department of Biotechnology (DBT). The ribbon-cutting ceremony symbolised India’s growing influence in the global biotech innovation space. The core pillars of the collaboration include: Capacity Building: Launching comprehensive training programs to upskill clinicians, scientists, and technicians in CGT manufacturing, analytics, and quality control. Research Collaboration: Driving academic and multi-centre clinical studies that address pressing medical needs, especially in the fields of oncology, autoimmune disorders, and rare diseases. Localised Manufacturing: Establishing PoC CAR-T centres across the country using Miltenyi’s CliniMACS Prodigy system, a move aimed at making cell therapies more accessible and cost-effective. Startup Ecosystem Support: Encouraging innovation by identifying and nurturing Indian biotech startups, aligned with the ‘Make in India’ initiative, and enabling local production of critical components. Commenting on the development, Priya Kapoor-Hingorani, Managing Director of Miltenyi Biotec India, said, “The potential of India draws us. Our partnership with BIRAC focuses on updating and upskilling scientists to strengthen the country’s scientific capabilities and infrastructure. Together, we’re exploring how to address current unmet needs in medical science, particularly in areas like autoimmune and rare diseases by enhancing access through innovative mechanisms such as point-of-care CAR-T and graft engineering.” Dr. Jitendra Kumar, Managing Director, BIRAC, also emphasised the strategic significance of the collaboration, stating, “The government is signing this Letter of Intent with a multinational company renowned for its expertise in cell and gene therapy. India aspires to become a global leader in this space, and achieving that goal requires a strong foundation of skilled manpower. Miltenyi has committed to supporting this vision by contributing to training and capacity building.” Source: eHealth #healthcarestartupindia #dseidehealthcarenetwork

Quadria Group, one of Asia’s most prominent healthcare-focused private equity firms, has unveiled the third edition of its HealthQuad fund, targeting a raise of up to $300 million, comprising a $200 million target corpus and a $100 million greenshoe option. HealthQuad Fund III builds upon the success of its predecessors, Funds I and II, which backed more than 18 tech-enabled healthcare ventures across diagnostics, mental health, e-pharmacy, and data analytics. Qure.ai, Medikabazaar, Ekincare, Wysa, and Redcliffe Labs are some of its portfolio companies. Launched in 2016 as a specialized vehicle distinct from Quadria’s flagship fund, HealthQuad has focused on identifying early-growth opportunities that improve access, affordability, and outcomes in India’s fragmented healthcare landscape. The new fund, according to the firm, will continue to back ventures across South Asia, Southeast Asia, and the GCC, with a focus on scaling impact across the primary, diagnostic, and chronic care spectrum. In a significant structural move, Quadria’s co-founders Dr. Amit Varma, Abrar Mir, and Sunil Thakur will now assume full ownership and operational control of HealthQuad following its separation from KOIS. A major portion of the existing investment and committee members will remain involved in managing current portfolio investments. The team is also set to expand, with additional hires expected across investing, operations, and clinical domains. "India presents one of the world's most compelling healthcare investment opportunities—driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care," said Dr Amit Varma, Co-founder and Investment Committee Member, HealthQuad. "With expanded leadership, we are better positioned than ever to deliver cross-regional value across South Asia, Southeast Asia, and the GCC." HealthQuad’s next phase comes on the heels of Quadria’s recent closure of its flagship Quadria Capital Fund III at $1.07 billion. The firm currently manages more than $4 billion in assets across 27 portfolio companies, with exposure in India, Vietnam, Indonesia, Malaysia, and Singapore. "HealthQuad is not just a fund—it's Quadria's conviction in motion," said Abrar Mir, Co-founder and Investment Committee Member. "We've built a unique platform supporting diverse healthcare models, accelerating their growth with our powerful ecosystem." Source: Indian Startup News #healthcarestartupindia #dseidehealthcarenetwork

New Delhi, 17th June 2025: Online Chikitsa Mitra (OCM), India’s leading health-tech start-up, is proud to announce the launch of its mobile app, a groundbreaking step toward expanding healthcare access across India by enabling direct, in-home consultations. This first-of-its-kind app offers consultations with specialized doctors in both Hindi & English. Founded in 2016, OCM started off in rural India by setting up e-clinics through local medical stores. Having connected thousands of rural residents to quality healthcare, facilitating over 120,000 consultations across 15+ states through its 550+ e-clinic network, OCM will now offer digital consultation pan-India through its newly launched app. This will give direct accessibility to the end users, thereby removing geographical barriers and enabling timely consultations with qualified specialists, general practitioners and wellness advisors, from anywhere in the country. In a nation of 1.44 billion people, only 12% regularly speak English. However, it has the world’s second-largest internet population at over 1.2 billion mobile users. Recognizing this disparity, the OCM app provides an intuitive, bilingual interface that bridges the gap, empowering patients to engage with healthcare professionals more readily than ever before. According to the Health Dynamics of India 2022-23 report from the Union Health Ministry, nearly 80% of rural community health centers (CHCs) face a shortage of specialized doctors. OCM’s app addresses this critical gap by providing an array of specialists in fields like cardiology, orthopedics, gynecology, pediatrics, and more, expanding healthcare options for underserved regions. “Our ultimate goal is to make healthcare a right, not a privilege, for all by scaling technology-driven solutions that meet evolving healthcare needs. With our mobile app, we are embracing the digital transformation sweeping across India to bring healthcare to the fingertips of people in even the remotest of locations,” said Smriti Tandon, Co-founder of OCM. Adding to this, Shubhang Tandon, Co-founder of OCM shared, “The shortage of specialists in semi-urban and rural healthcare facilities is a reality that affects millions. Through our app, we’re utilizing technology to connect these patients with top-tier specialists, empowering communities with a lifeline that’s convenient, effective, and life-changing.” Patients can easily schedule appointments, engage in secure video consultations, and receive digital prescriptions through the app. It is available for download on both Android and iOS platforms. Looking ahead, OCM aims to onboard more doctors across various specialties and achieve 1,000 consultations per day by the end of 2025-26. Source: passionate in marketing #healthtechstartup #dseidehealthcarenetwork

A deadly, drug-resistant fungus, Aspergillus fumigatus, is spreading rapidly across the US, posing serious risks to people with weak immunity as climate change fuels its growth and resistance. Aspergillus fumigatus, a dangerous fungus that can rot human tissue and cause life-threatening infections, is spreading fast across the United States and experts say the threat could get worse with rising temperatures. This airborne fungus, which releases microscopic spores, is nearly impossible to avoid and can lead to serious health complications, especially in people with weakened immune systems. There are several forms of aspergillosis. One of the most concerning is invasive aspergillosis, a rare but often deadly infection that can spread from the lungs to the brain, heart, or kidneys. Another is chronic pulmonary aspergillosis, which affects around 400,000 people globally and causes long-term damage to the lungs. SOURCE- Financial express

The Chief Minister emphasized that improving healthcare and medical education is a top priority for his government, not only to ensure better patient care but also to raise Telangana’s reputation in the national medical education landscape. He instructed health officials to coordinate closely with the Union Health Ministry to expedite pending approvals for new colleges and secure additional central funding where needed. The reforms will also include upgrading hospital infrastructure, streamlining administrative systems, and implementing real-time digital dashboards to monitor performance indicators across all government medical colleges and hospitals. Revanth Reddy also underscored the importance of timely execution, directing that funds be released without delay and responsibilities clearly assigned to senior officers. Additionally, the government aims to make Telangana a hub for skilled nursing professionals by integrating language training—starting with Japanese—into nursing curricula, in collaboration with the Japanese government. This move is intended to increase overseas employment opportunities for nursing graduates. The Chief Minister’s overhaul plan is being viewed as a proactive response to institutional challenges that have persisted for years, and as a foundational step toward building a more accountable, efficient, and globally relevant public healthcare system in Telangana. Source: The economic times #healthcarefunding #dseidehealthcarenetwork

India has been one of the top recipients of remittances in the world for more than a decade. Inward remittances jumped from $55.6 billion in 2010-11 to $118.7 billion in 2023-24, according to data from the country’s central bank. The bank projects that figure will reach $160 billion in 2029. This means there is an increasing market for digitalized banking experiences for non-resident Indians(NRIs), ranging from remittances to investing in different assets back home. Aspora (formerly Vance) is trying to build a verticalized financial experience for the Indian diaspora by keeping convenience at the center. While a lot of financial products are in its future roadmap, the company currently focuses largely on remittances. “While multiple financial products for non-resident Indians exist, they don’t know about them because there is no digital journey for them. They possibly use the same banking app as residents, which makes it harder for them to discover products catered towards them,” Garg said. In the last year, the company has grown the volume of remittances by 6x — from $400 million to $2 billion in yearly volume processed. With this growth, the company has attracted a lot of investor interest. It raised $35 million in Series A funding last December — which was previously unreported — led by Sequoia with participation from Greylock, Y Combinator, Hummingbird Ventures, and Global Founders Capital. The round pegged the company’s valuation at $150 million. In the four months following, the company tripled its transaction volume, prompting investors to put in more money. The company announced today it has raised $50 million in Series B funding, co-led by Sequoia and Greylock, with Hummingbird, Quantum Light Ventures, and Y Combinator also contributing to the round. The startup said this round values the company at $500 million. The startup has raised over $99 million in funding to date. After pivoting from being Pipe.com for India, the company started by offering remittance for NRIs in the U.K. in 2023 and has expanded its presence in other markets, including Europe and the United Arab Emirates. It charges a flat fee for money transfer and offers a competitive rate. Now it also allows customers to invest in mutual funds in India. The startup markets its exchange rates as “Google rate” as customers often search for currency conversion rates, even though they may not reflect live rates. The startup is also set to launch in the U.S., one of the biggest remittance corridors to India, next month. Plus, it plans to open up shop in Canada, Singapore, and Australia by the fourth quarter of this year. Source: yahoo finance #healthcarestartupindia #dseidehealthcarenetwork

Indian benchmark indices settled sharply lower on Friday on the back of weak global cues due to geopolitical concerns and consistent foreign outflows. Market is on risk aversion mode after Israel’s military strike on Iran. BSE Sensex tanked 573.38 points, or 0.70 per cent, to settle at 81,118.60, while NSE's Nifty50 plunged 169.60 points, or 0.68 per cent to close at 24,718.60 for the day. Select buzzing stocks including Glenmark Pharmaceuticals Ltd, Valor Estate Ltd (D B Realty Ltd) and Max Healthcare Institute Ltd are likely to remain under the spotlight of traders for the session today. Here is what analysts at Axis Securities have to say about these stocks ahead of Monday's trading session: Valor Estate | Buy | Target Price: Rs 266-275 | Stop Loss: 208 Valor Estate (formerly known as DB Realty) has delivered a decisive breakout above the multiple resistance zone near Rs 235 on the weekly chart, confirmed by a strong bullish candle, signalling the start of a medium-term uptrend. Surge in volume during the breakout underscores robust market participation, adding conviction to the validity of the breakout. A weekly close above the upper Bollinger Band has triggered a fresh technical buy signal, pointing to strengthening bullish undertones. Both daily and weekly RSI are holding above their respective reference lines, reinforcing a positive. Analysis indicates an upside potential toward Rs 266-275 levels. SOURCE-Business Today #StockMarket #Investing #GlenmarkPharma #MaxHealthcare #ValorEstate #AxisSecurities #StockTips #ShareMarketIndia #PharmaStocks #HealthcareStocks

Here are the latest reports on this tragic incident: A Boeing 787‑8 Dreamliner, Air India Flight AI 171, bound from Ahmedabad to London, crashed just 30 seconds after takeoff on June 12, 2025. The aircraft struck the dining hall of the doctors’ hostel at B.J. Medical College around lunchtime, causing a devastating fireball  Tragically, 241 of 242 people on board were killed, with only one survivor  On the ground, initial reports confirm 24 fatalities, including four MBBS students, a doctor’s wife, and other residents; two more students are still missing  Key victim data: The four MBBS students were from B.J. Medical College—two first-year and two second-year undergraduates  Two students remain unaccounted for . The flight data recorder (black box) has been recovered from the debris atop the hostel mess building and is being analyzed for clues on factors like engine thrust, flap settings, and landing gear  Preliminary investigations focus on possible mechanical or procedural issues during takeoff  In response, India’s aviation regulator has ordered additional safety inspections on all Boeing 787‑8/9 aircraft in Air India’s fleet  International agencies, along with Boeing and GE Aerospace, are collaborating in the investigation  ⚠️ This remains India’s deadliest aviation tragedy in over 30 years, and families of the victims—including medical students—are receiving support. DNA testing is underway to confirm identities Source: onmanorama #AirIndiaCrash #BJMedicalCollege #MedicalStudents #AhmedabadCrash #dseidehealthcarenetwork

Healthcare organizations today face growing cyber threats—from ransomware attacks to data breaches targeting patient records. With outdated systems and limited IT resources, many struggle to keep pace. In contrast, Fortune 500 companies have invested heavily in robust cybersecurity strategies. So, what can healthcare leaders learn from them? Zero Trust Architecture Lesson: Fortune 500 firms adopt "never trust, always verify" models to prevent lateral movement of attackers within systems. Healthcare Takeaway: Implement role-based access, multi-factor authentication, and micro-segmentation. Proactive Threat Hunting Lesson: Enterprises actively look for threats using AI and analytics before damage occurs. Healthcare Takeaway: Invest in Security Operations Centers (SOCs) or partner with managed detection and response (MDR) providers. Employee Cyber Hygiene Training Lesson: Regular phishing simulations and awareness training are core in Fortune 500 firms. Healthcare Takeaway: Train staff across departments—clinicians, admin, IT—to spot and report threats. Real-Time Incident Response Playbooks Lesson: Fortune 500s run frequent cyber drills and have pre-approved breach response plans. Healthcare Takeaway: Prepare for worst-case scenarios with defined roles, communication protocols, and backup systems. Vendor Risk Management Lesson: Enterprises assess third-party vendors thoroughly. Healthcare Takeaway: Conduct cybersecurity audits on EHR providers, telemedicine platforms, and IoT medical device vendors. Cloud Security Best Practices Lesson: The cloud isn’t inherently secure—leading companies apply encryption, access control, and regular audits. Healthcare Takeaway: Apply HIPAA-compliant cloud configurations and encrypt PHI (protected health information). SOURCE- CIO #HealthcareCybersecurity #CyberSecurity #DigitalHealthSecurity #DataProtection #HealthcareIT #PatientDataSecurity#HealthTech #ZeroTrust #RansomwareProtection #HIPAACompliance

From foetal ultrasound dating and high-risk-pregnancy guidance to virtual autopsies and clinical chatbots AI tools are quietly reshaping Indian healthcare. Researchers at IIT-Madras and the Translational Health Science and Technology Institute in Faridabad are developing an artificially intelligent (AI) model to use ultrasonography pictures to predict the age of a growing foetus. Called Garbhini-GA2, the model was trained on scans from about 3,500 pregnant women who had visited the Gurugram Civil Hospital in Haryana. Each scan labelled different parts of the foetus, its size, and its weight — measures that can be used to predict a foetus’s age. After the training, team members tested it with (unlabelled) scans from 1,500 pregnant women who had visited the same hospital and around 1,000 pregnant women who had visited the Christian Medical College Vellore. They found Garbhini-GA2 erred on the age of the foetus by only half a day. This is a significant improvement over the most common method today: using Hadlock’s formula. Because the formula is based on data from Caucasian populations, it has been known to miss the age of the foetus in India by up to seven days, according to the IIT-Madras team. SOURCE- THE HINDU #Healthcare #AIinHealthcare #AIsaftey #Humanhealth

Apollo Cradle & Children's Hospital plans to open 7–8 new maternal and child healthcare centres across India over the next five years, following recent launches in Mumbai and Hyderabad Currently operates 19 centres in cities like Hyderabad, Bengaluru, Delhi NCR, Chennai, and Amritsar, offering comprehensive services—maternity, neonatology, paediatrics, gynaecology, fertility, and fetal medicine. Existing units are being enhanced with larger facilities and improved infrastructure to better accommodate patient demand. The hospital’s app and website provide continuous pregnancy guidance, postpartum care support, a symptom checker, and early parenting tools. SOURCE- THE ECONOMIC TIMES #ApolloCradleExpansion #MaternalHealth #ChildcareIndia #HealthcareInnovation #ApolloHospitals #DigitalHealth #IndiaHealthMarket #WomenAndChildCare

In India, the first 1,000 days of a child’s life are rightly viewed as critical to nutrition, brain development, and immunity. But one equally essential area often goes overlooked: skin health. For millions of Indian parents, the daily routine of massaging, bathing, and moisturising newborns has remained unchanged for generations. Yet, the products they use are often poorly suited for Indian skin, water, and climate. Dr. Sonali Kohli, ( a board-certified dermatologist with over a decade of experience with handling skin ), first encountered this gap not just in her clinic, but in her own home. This frustration became the founding insight behind EDA Baby & Child, a dermatology-led skincare startup that wants to revolutionise how Indian parents think about baby skincare. What began as a personal need has now grown into a science-first consumer brand with a clear mission: to build India’s first clinically validated, complete child wellness ecosystem. Solving the cracks in the international formula There’s no doubt the global baby skincare market is booming—expected to reach $20.3 billion by 2031, according to Transparency Market Research—but Indian parents are beginning to question the dominance of international brands. The underlying issue? Indian babies are fundamentally different ( in their genetics and environmental exposure). Baby skin barrier is 40% thinner than adults and far more permeable to pollutants, allergens, and pH imbalance from hard water or harsh soaps. And beyond biology, the everyday environmental stressors in Indian cities—dust, heat, varying humidity—require tailored skincare solutions. Through her clinical practice, Dr. Kohli observed that global formulations, though well-researched for Western environments, were inadequate in India. “International brands can many a times overlook the differences in Indian skin genetic predisposition, melanin levels, and our water’s mineral composition,” she explains. To build EDA, she spent two years studying baby skin reactions and rashes across India’s micro-climates—from the humid coastlines of Kerala to the dry winters of North India. The result is a line of ceramide-rich, barrier enhancing, pH-balanced formulations engineered for Indian skin. Source: Indian startup news #healthcarestartup #dseidehealthcarenetwork

Fortis Healthcare's stock has reached a new 52-week high of Rs. 768.7, following a strong performance despite recent underperformance relative to its sector. The stock has shown positive momentum, trading above key moving averages, and has delivered a notable annual return, significantly outpacing the Sensex.

Deep‑Tech Revolution in India 1. Government-Fueled Momentum Major funding boosts: Initiatives like the India AI Mission (₹10,372 crore over five years) and proposed deep-tech fund (₹20,000 crore) are propelling innovation Policy frameworks taking shape: Policies such as the National Deep Tech Startup Policy aim to streamline ecosystem growth from R&D to scaling 2. Startup Ecosystem Gains Ground Robust startup numbers: Over 3,600 deep‑tech startups exist in India today, including nearly 500 launched in 2023 alone Global competitiveness: Ranked 6th globally for deep-tech startups—AI dominates, showing 74% of new ventures and 86% of funded ones tied to AI 3. Sector Focus & R&D Intensity Core verticals targeted: AI, ML, robotics, quantum, biotech, advanced materials, drones, and blockchain are at the forefront drishtiias.com Long R&D cycles, far-reaching impact: Deep-tech requires intensive investment and patience but holds the promise of disruptive breakthroughs 4. Funding & Investment Trends Rising capital inflows: Globally, deep-tech is garnering 20% of annual VC funds (~$40 billion in 2023)—mirrored by India’s. India-specific investments: Deep‑tech startups like Observe.AI have logged major funding (e.g. $214 M), while national policy funds are being calibrated to match demand drishtiias.com . 5. Opportunities & Challenges 👉 Strengths: Deep talent pool—~1.5 million engineering grads annually—fuels innovation DPI backbone (UPI, Aadhaar, ONDC) supports scalable digital solutions . ⚠️ Challenges: Regulatory hurdles, commercialization lag, talent shortages, and infrastructure limitations persist Execution gaps are noted—policy intent doesn't always translate into action without public-private collaboration . 6. The Role of Thought Leaders Influencers like Jeenendra Bhandari (often leading deep-tech councils and VC platforms) typically emphasize: Aligning policy with operational execution. Encouraging patient, long‑term capital for high‑risk deep-tech ventures. Strengthening academia-industry synergies for commercializing R&D. Building market access pathways through anchor customers and public procurement. Source: Economic times #healthcarestartupindia #dseidehealthcarenetwork

Tucked inside the Tis Hazari courts complex, a yellow-painted health outpost, once a Mohalla Clinic, now wears new branding: Urban-Ayushman Arogya Mandir (U-AAM), announced through placards and signboards in Hindi and English. Upgradation of Mohalla Clinics & Dispensaries Over 500 Mohalla Clinics and several dispensaries are being upgraded to full-fledged Urban Ayushman Arogya Mandirs (AAMs) and PHCs. The Delhi government has identified close to 968–1,139 sites for these centre Expanded Diagnostic & Preventive Care New centres provide a wide range of free diagnostic tests—including diabetes, malaria, TB, HIV, syphilis, dengue, JE, ECGs, X‑rays, and Hepatitis B screening—reflected in the NEDL recommendations. Day‑Care Services PHCs now offer short‑term (same‑day) daycare admissions for common ailments like fever or diarrhea, minimizing hospital referrals SOURCE- THE HINDU #DelhiHealthReform #AyushmanArogyaMandir #MoreTestsLessWait #ZeroCostCare #TechAtPrimaryCare #WellnessAtDoorstep #PHCUplift

Apollo Hospitals Enterprise Ltd. has shown significant market activity, maintaining its opening price throughout the trading session. The company has outperformed the Sensex over the past year, with a market capitalization of Rs 98,775.75 crore and a P/E ratio above the industry average, reflecting strong earnings potential. Apollo Hospitals Enterprise Ltd., a prominent player in the hospital and healthcare services sector, has shown notable activity today, reflecting a complex market environment. The stock opened at Rs 6,842.45 and has maintained this price throughout the trading session. Despite a slight decline of 0.07% today, Apollo Hospitals has outperformed the Sensex over the past year, achieving a return of 15.34% compared to the Sensex's 8.29%. The company's market capitalization stands at Rs 98,775.75 crore, categorizing it as a large-cap entity. With a price-to-earnings (P/E) ratio of 68.36, Apollo Hospitals is positioned above the industry average P/E of 54.05, indicating strong earnings potential relative to its peers. In terms of moving averages, the stock is currently higher than its 100-day moving average but lower than its 5-day, 20-day, 50-day, and 200-day averages, suggesting a mixed short-term performance. The broader hospital and healthcare services sector has seen 41 stocks declare results, with 13 reporting positive outcomes, indicating a competitive landscape. Overall, Apollo Hospitals continues to demonstrate resilience in a fluctuating market. Source: marketsmojo #healthcarenews #dseidehealthcarenetwork

HealthKois is aiming at a first close at the end of this year or early 2026. The investments will be deployed over the next four years, with ticket size of each of the investments likely in the range of $7 million to $25 million. "We are looking at a $300 million fund with a green shoe option of another $100 million," said Ajay Mahipal, partner at HealthKois. "We are looking at 13-16 portfolio companies in the HealthKois fund," he said. HealthKois, a Delhi-based growth stage venture capital fund, plans to roll out a $400-million fund to invest in India's healthcare sector. The fund intends to target companies in AI-led healthtech, medtech, biopharma, healthcare delivery and climate health, its managing partner Charles Janssen told ET in an exclusive interaction. "We have started raising this fund from LPs (limited partners). Our LPs are split between Asia, Europe, and the US," Janssen said. HealthKois is aiming at a first close at the end of this year or early 2026. The investments will be deployed over the next four years, with ticket size of each of the investments likely in the range of $7 million to $25 million. "We are looking at a $300 million fund with a green shoe option of another $100 million," said Ajay Mahipal, partner at HealthKois. "We are looking at 13-16 portfolio companies in the HealthKois fund," he said. Source- The Economic Times #HealthcareInvestment #VentureCapital #HealthTech #MedTech #DigitalHealth

Tracxn’s India Pharma and Healthcare Funding Tracker for May 2025 reveals a major recovery in funding activity. Total funding reached $254.7 million across 10 rounds, representing a 462.36 per cent increase from April 2025 and a 44.20 per cent rise from the same month last year. Seed-stage funding dominated with 61.9 per cent of total funding. Early-stage funding contributed 18.0 per cent, while late-stage funding comprised 20.1 per cent of the total. PB Healthcare secured funding of $156 million followed by Vetic ($26.2 million), Pharmazz: ($25.0 million), CureBay ($21.0 million), The Good Bug ($11.9 million), and DentCare ($10.6 million). In May 2025, several prominent venture capital firms made notable investments in the startup ecosystem. Bessemer Venture Partners participated in a funding round for Vetic, while Bertelsmann India Investments backed CureBay, and SIG Venture Capital invested in The Good Bug. Each of these firms was involved in one funding round, highlighting selective but strategic investment activity during the month. Key Takeaways: 1. Massive recovery in funding: Funding surged more than 5 times compared to April 2025. 2. Seed-stage rounds lead: Seed investments made up the largest share at over 60 per cent. 3. The top deal alone ($156 million) drove the majority of funding. This surge suggests renewed investor confidence and growing momentum in India’s pharma and healthcare startup ecosystem. Source: Express Healthcare #healthcarestartupfunding #dseidehealthcarenetwork

Blue Jet Healthcare has recently experienced a change in its evaluation, reflecting strong financial performance, particularly in Q4 FY24-25, with significant profit growth. The company has outperformed the broader market over the past year and maintains a strong market position, despite some long-term growth concerns. Q3 FY25 Financial Highlights Revenue: ₹3,183.82 million, marking a 91% year-on-year (YoY) increase and a 53% quarter-on-quarter (QoQ) growth. Net Profit: ₹989.83 million, up 208.4% YoY and 69.6% QoQ. EBITDA: ₹1,324.94 million, reflecting a 147.9% YoY rise. EBITDA Margin: Expanded by 630 basis points to 39.0%. Earnings Per Share (EPS): ₹5.71, compared to ₹1.85 in Q3 FY24. Strategic Initiatives and Market Position R&D Investment: The company announced a ₹40 crore investment to establish a dedicated Research & Development facility, aiming to bolster innovation in Active Pharmaceutical Ingredients (APIs) and pharma intermediates . Market Performance: Blue Jet Healthcare's stock achieved a new 52-week high of ₹954, reflecting strong investor confidence and a significant market capitalization of ₹16,123 crore SOURCE-Marketsmojo #FinancialPerformance #QuarterlyResults #StockMarket #MarketOutperformance #PharmaStocks #HealthcareNews

Around 20% of these centres have expanded their footprint across three or more cities, signalling a trend towards multi-city operations. Over 15% of all global capability centre (GCC) employees in India are involved in the healthcare and life sciences sector, reflecting the sector’s growing importance within the country’s global services landscape, according to recent reports. Moreover, a significant share—over 55%—of these GCCs are backed by US-headquartered companies, underlining the sector’s strong international roots. Geographically, around 85% of healthcare and Life Sciences GCCs are concentrated in four major hubs: Bengaluru, Hyderabad, Mumbai, and Delhi-NCR. Bengaluru leads with nearly 33% of the total centres, followed closely by Hyderabad and Mumbai. SOURCE- Analytics India Magazine #PharmaInnovation #HealthcareInnovation #GCC2025 #GlobalCapabilityCenters #PharmaGCC #HealthcareGCC

On May 12, 2023, Dr. Atul Goel, who was serving as the Director General of Health Services (DGHS) at the time and held the post until April 2025, issued a contentious circular that sent ripples through India’s healthcare system. The directive, addressed to Central Government Hospitals, CGHS Wellness Centers, and Polyclinics, mandated strict adherence to prescribing only generic medicines. The move, aimed at reducing healthcare costs and curbing pharmaceutical influence, has ignited a fierce debate among doctors, patients, and policymakers. While the government touts affordability and equity, critics argue the policy is premature, citing quality concerns, supply chain issues, and loss of medical autonomy. The circular reiterated a standing instruction: all doctors, including residents, in Central Government healthcare facilities must prescribe generic medicines only. Despite repeated directives, the DGHS noted persistent non-compliance, with some doctors continuing to prescribe branded drugs. This practice, the circular stated, was viewed “strictly” by the competent authority. SOURCE- THE PROBE #Healthcrisis #Drugs #healthcare

At the CII Annual General Meeting, startup founders and investors called for the need for policy stability, more patient capital, and global competitiveness, even as India emerges as a hub for innovation and entrepreneurship. Rajat Verma, founder and CEO of battery recycling startup Lohum, pointed out the mismatch between India’s global ambitions and the depth of its private capital markets. “There’s no dearth of engineering talent or market opportunity,” he said, “but a lot of promising deep-tech entrepreneurs are unable to scale simply because long-gestation sectors lack the capital support they need.” Drawing on InMobi’s journey from a scrappy startup in 2007 to one of the world’s largest independent ad tech firms, Dr Subi Chaturvedi, global senior VP at InMobi emphasised that the current startup generation doesn’t seek subsidies or hand-holding—just clarity. “Policy cannot be an afterthought,” she said. “What we need is consistency, not volatility. Without that, global investors will hesitate to back Indian innovation.” On the other hand, Paavan Nanda, CEO and co-founder of WinZo Games thinks that what every entrepreneur in India needs is “exposure”. “Exposure is the single most important unlock that any entrepreneur can get, especially if they're looking to expand globally. We're talking about Indian games to hold top 3 ranking across all countries.” The discussion also turned to the broader issue of narrative—how Indian startups are viewed, both at home and abroad. Suhel Seth, who joined the panel to provide an outside-in view, didn’t hold back. “Today, the startup ecosystem is largely measured by valuations and unicorn status,” he said, “but that’s not the right yardstick. The real question is—are we solving unique, replicable problems that change how people live, behave, and consume?” He added that Indian startups must lead not just with scale, but with pride and values. “Why haven’t we built a Google or Facebook? It's because we often celebrate exits more than endurance,” Seth said, urging founders to spotlight impact over investor returns. Healthcare, gaming, deep tech and financial inclusion were all cited as sectors where Indian companies could lead globally—but only if backed by the right ecosystem. Siddhartha Nihalani, CEO and co-founder of Practo, noted that India is well-placed to become a hub for medical tourism, but needs to resolve challenges around global credentialing and remote care. “We’ve got the doctors, the hospitals and the tech. But there are regulatory challenges around education, around privileging these doctors in their respective countries, which is something that governments of countries can work together and figure out – and which country recognises which medical degree across countries.” Throughout the discussion, the emphasis remained on thinking big—but thinking Indian. 60% of the cost of any military equipment today is made up of electronics – 35% of that is semiconductors. China's penetration of that market has increased 600%, including U.S. defence supply chains in the last couple of years from 2004 to 2022. And what’s more, by 2030, China will have 65% of global capacity on semiconductors and electronics for defence. “That's the piece that we're up against. Now, why India? India is the only country with enough skilled manpower to be able to compete with China. Why? Because since the 70s, American companies have come to India, European companies have come to India and set up huge tech centres over here. So, our GCCs are finally paying off,” explains Vrinda Kapoor of 3rdiTech. 20% of the world's entire semiconductor design talent sits out of three Indian cities – Bangalore, Hyderabad and Mumbai. Qualcomm's 5G chip was 100% designed in India. Source: fortuneindia #healthcarestartup #dseidehealthcarenetwork

JP Nadda, Union Minister for Health & Family Welfare, Chemicals & Fertiliser, on Thursday said that Public-private partnerships can be instrumental in ensuring that early detection and preventive healthcare reach every corner of the country Public-private partnerships can be instrumental in ensuring that early detection and preventive healthcare reach every corner of the country, the Union Health Minister JP Nadda said on Thursday. Speaking to reporters in New Delhi on the sidelines of the Confederation Of Indian Industry (CII) Annual Business Summit-2025, Nadda emphasised the pivotal role of the private sector in driving India's healthcare, seeking the private sector to innovate in AI and tech-based innovations to enable mass screenings and telemedicine throughout the healthcare ecosystem. "Health transformation doesn't happen overnight," the Union Minister said stressing on the need to strategise to build systems that will serve future generations. In his address to the CII summit, Nadda, emphasised the theme "Building Trust- India First" and called for a unified national effort to strengthen healthcare systems aligned with India's 2047 development roadmap. He underlining the government's unwavering commitment to healthcare reforms, innovation and accessibility, with a compelling vision for a healthier, more inclusive India. SOURCE- THE TRIBUNE INDIA

India recently crossed 1,000 Covid cases nationwide, raising questions on the country’s healthcare system. According to experts, this surge involves milder variants, but the spike tests a system already stretched thin by underinvestment, doctor shortages, and gaps in hospital infrastructure. India’s National Health Policy, 2017, set a target of spending 2.5 per cent of gross domestic product (GDP) on health care by 2025. However, the current spending remains at 1.4 per cent. Without an investment boost, experts warn that India will struggle to meet both everyday and emergency health demands. SOURCE-Business Standard #covid19 #healthcare #Datanomics #IndiaHealthcare

After COVID-19, digital healthcare saw an increasing global interest. Digital technologies can be instrumental for tracking epidemics, limiting transmission, developing new drugs and diagnostics, and advancing medical research to improve well-being. The World Health Organisation (WHO) issued guidelines to help countries implement technology in healthcare on a large scale. Countries like UK and US have already adopted digital technologies in health, including electronic health and medical records to improve healthcare. These aim to streamline and expand access to healthcare services by digitising patient data. India is following a similar trend, with initiatives like Ayushman Bharat Digital Mission (ABDM) aiming to address long-standing issues in India’s healthcare access, quality, and affordability, factors that push 60 million people into poverty each year. While the use of technology in healthcare sounds promising, collecting electronic medical and health records for 1.4 billion citizens is complex, and may face challenges such as discrepancies in data collection, resources, and competing interests of stakeholders. Even during COVID-19, there was no clear data on deaths or shortages in services like oxygen, hospital beds, and medicines. While this would affect everyone, those facing socio-economic injustice are at greater risk. Digitising healthcare, for example, requires resources, which service providers may be reluctant to invest in. Large healthcare providers may face disruption, while smaller platforms will struggle with the resource-intensive nature of digitisation. This has led to resistance to the ABDM, particularly from stakeholders within the medical community. A major factor is the shortage of medical doctors, with the current number just exceeding one-fourth of the WHO’s recommended threshold. Doctors are expected to upload patient data themselves, yet the average Indian doctor is understood to be seeing 40-60 patients a day, leaving little time for this. With consultations lasting only two minutes, healthcare professionals may overlook digital records even if available. SOURCE-THE WIRE #Healthcare #DigitalHealth #HealthTech #PublicHealth #HealthInfrastructure #HealthcareChallenges #HealthSystemStrengthening #TechVsInfrastructure #HealthEquity #HealthInnovation

Qure.ai, the fast growing Indian health-tech startup that offers artificial intelligence (AI) solutions for medical diagnostics, is planning to go public in next two years, says its co-founder and CEO Prashant Warier. Founded in 2016 and headquartered in Mumbai, Qure.ai has developed advanced AI algorithms that help healthcare providers detect critical conditions like tuberculosis, lung cancer and stroke risks. These tools that analyse medical images to give fast and accurate diagnosis are being increasingly used in regions with shortage of trained radiologists. Warier stated in media, “We look to break even and be profitable next financial year. As we sort of get to that break-even, we can start planning. And maybe in two-and-a-half years or two years is the earliest we can do an IPO.” The company has already got significant backing from global investors. Qure.ai has raised USD 125 million (~INR 1,063 crore) so far with Fractal Analytics, Peak XV Partners and Novo Holdings—the investment arm of Danish pharma giant Novo Nordisk—as its top backers. Global Expansion with US as Key Market Qure.ai’s solutions have got traction with major global healthcare players. Its client list includes AstraZeneca, Medtronic and Johnson & Johnson MedTech with whom it is partnering in India to detect early lung cancer. Currently, US accounts for around 25% of the company’s revenue, making it Qure.ai’s largest market. The company is now looking to go deeper in US through new partnerships. At the same time, it is also focusing on expansion in low and middle income regions in Latin America and Africa to bridge diagnostic gaps in underserved healthcare systems. Interestingly, India is a minor market contributing less than 5% of overall revenue. Growth Trajectory in a Booming Industry Qure.ai has seen 60–70% annual revenue growth and Warier expects this to continue for next five years. The company currently sees around 15 million patients globally each year and this number will go up as AI driven diagnostic tools become more mainstream. The optimism around Qure.ai is in line with industry trends. The global AI in healthcare market which is estimated to be USD 14.92 billion (~INR 1.26 lakh crore) in 2024 is expected to reach USD 110 billion (~INR 9.36 lakh crore) by 2030 as AI tools for early disease detection, workflow automation and reducing the burden on overworked healthcare professionals gain traction. Strategic Outlook While profitability is the goal for next financial year, an IPO is clearly on the cards. Warier said achieving financial sustainability will be a key milestone before public listing. With its pioneering AI technologies, international clientele, and expanding footprint across developed and emerging markets, Qure.ai is positioning itself as a formidable player in the global health-tech landscape. If current growth trends continue, the company could well be one of India’s most prominent AI-based healthcare success stories to enter the public markets in the near future. For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central. Source: ipocentral.in #healthcarestartup #dseidehealthcarenetwork

Fintech dominated the sector-wise distribution with three deals, followed by strong performances from e-commerce and media and entertainment. This week’s funding activity featured five growth-stage and 13 early-stage deals, with three startups choosing to keep their funding amounts private. Mumbai: Indian startups raised $139.5 million this week across 21 deals -- reflecting continued investor confidence despite broader market uncertainties. This week’s funding activity featured five growth-stage and 13 early-stage deals, with three startups choosing to keep their funding amounts private. Delhi-NCR emerged as the leading region with eight deals, followed by Bengaluru with four. Startups from Mumbai, Chennai, Bhubaneswar, and Ahmedabad also featured in this week’s funding round-up. Source: freepressjournal #healthtechstartup #dseidehealthcarenetwork

Dr. Atul Mohan Kochhar, CEO of the National Accreditation Board for Hospitals and Healthcare Providers (NABH), has reaffirmed the organization's zero-tolerance policy towards tampering, forgery, and falsification of documents submitted for accreditation and certification processes. “Tampering, falsification, and misrepresentation will not be tolerated in any form,” Dr. Kochhar said, emphasizing that NABH is committed to upholding the integrity of its accreditation and certification systems. NABH has stipulated strict punitive measures against healthcare organizations (HCOs) found engaging in unethical or unlawful practices during the accreditation process. These measures include immediate closure of accreditation or certification applications, withdrawal of existing accreditation or certification status, a mandatory five-year bar from reapplying under any NABH programme, initiation of legal proceedings as deemed necessary and public disclosure of the names of defaulting organizations on the NABH website. The move comes amid increasing reports of hospitals submitting tampered statutory licenses, manipulated staff lists, altered infrastructure images, and forged documents to gain NABH accreditation or empanelment with regulatory bodies and insurance networks. Dr. Kochhar made it clear that the onus lies squarely on the hospital leadership, including owners, CEOs, and senior management, to ensure the accuracy and authenticity of all data and documents submitted to NABH. SOURCE- Pharmabiz.com #NABH #HealthcareCompliance #PatientSafety #MedicalEthics #HealthcareStandards #AccreditationAlert #HealthcareRegulation #NABHIndia #DocumentIntegrity #HealthcareTransparency #MedicalAccountability #HealthcareNews

E-clinic startup CureBay in India has bagged $21 million in a Series B funding round led by Bertelsmann India Investment. Elevar Equity and British International Investment also joined the fundraising event. Since launching in 2021, the company now has a chain of over 150 rural e-clinics across the states of Odisha and Chhattisgarh, employing over 1,000 community health workers, or Swasthya Mitras, who are trained to facilitate teleconsultations, diagnostic tests, medicine order and delivery, and hospital admission and concierge services. CureBay offers a preventive health service package to which around 90,000 are actively subscribed. WHAT IT'S FOR With its fresh funds, CureBay plans to deploy proprietary AI-powered algorithms to enable workflow automation and enhance the predictive capabilities of its rural e-clinic network. The startup has already integrated machine learning, generative AI, and Internet of Things diagnostics into its technology platform. "The capital will help us scale technology, talent, and reach to bring dignified, affordable healthcare to the last mile," added founder and CEO Priyadarshi Mohapatra. CureBay raised more than $13 million in Series A funding in two rounds over the past three years to build its network. It targets to set up 200 e-clinics in rural India. MARKET SNAPSHOT Indian health tech startups developing or integrating AI into their technology stack have attracted the most investments in recent years. For example, medical imaging startup Qure.ai raised $65 million in Series D funding in September, while dermatology startup Cureskin raked in $20 million in Series B funding in March last year. Dozee, which offers an AI-powered contactless vital signs monitoring and alert system, seeks to enter more international markets with its latest $8 million investment. Kauvery Hospital, through its investing arm, Healthcare Capital, provided undisclosed funding to remote patient monitoring system developer Lifesigns to help augment its AI and predictive algorithm capabilities. Early this year, BrainSight AI, which develops an AI-powered brain mapping platform, scored $5 million in pre-Series A funding, while Consint.AI, which offers generative AI-driven insurance technology solutions, raised $500,000 in seed funding. Source: mobihealthnews #healthcarestartup #fundingindia #dseidehealthcarenetwork

Lightbox-backed Zeno Health (erstwhile Generico) has launched a platform to incubate and support early stage healthcare startups. The platform, Pay It Forward, aims at nurturing healthcare and wellness startups operating in medicines, diagnostics, insurance, hygiene and nutrition categories. “Early stage healthcare and wellness startups working in medicines, diagnostics, insurance, hygiene, nutrition, preventive care, derma, OTC, or any other product or service that makes healthcare better and more accessible are invited to apply…,” Zeno Health said in a statement. With the initiative, the company looks to help startups by providing them retail shelf space and visibility in nearly 180 pharmacies and stores across Mumbai and Pune. The Mumbai-based startup claims to offer access to its consumer base and mentorship from its founders and leadership team. As per its statement, the programme will help startups that are providing quality healthcare at affordable costs. Founded by IIT Bombay alumni Girish Agarwal and Siddharth Gadia in 2017, Zeno Health is an omnichannel pharmacy network which sells generic medicines. It claims to offer medicines at 60% lower cost by sourcing them directly from manufacturers. Besides retail pharmacy stores, it has 200 micro-franchises across Maharashtra and West Bengal. Zeno Health also has a private label brand GoodAid which sells generic medicines. “Through ‘Pay It Forward’, we want to create a founder-first platform that helps startups bring impactful solutions to the people who need them most. We’re not taking equity. We’re not doing this for credit. We’re doing it because India needs more healthcare disruptors…,” said Agarwal. The development comes nearly over two months after the healthcare startup launched a 50-minute medicine delivery service in Mumbai. Prior to that, Zeno Health raised $25 Mn in its Series C funding round led by South Korean private equity firm STIC Investments and existing investor Lightbox. Back then, it said that the capital would be used to expand footprint, spruce up tech infrastructure, branding and building innovative solutions for diverse markets. Source: inc42 #healthcarestartupindia #dseidehealthcarenetwork

Fuze Health, a technology-powered healthcare solutions company committed to transforming patient experiences and advancing personalized care, launched today. The company is focused on enabling healthcare partners – including care providers, employers, health plans and life sciences companies – to excel in an outcomes-focused system and empowering patients to more comprehensively manage their health at home. Fuze Health evolves from the 2024 merger of virtual pharmacy pioneer Truepill and home health screening leader LetsGetChecked. Alto, a leading digital pharmacy with deep expertise in women’s health, joined the company this week. The combination is positioned to deliver more therapies and support to a greater number of patients in more locations, including in the home through innovative digital tools. “We are excited to launch Fuze Health with a vision to empower more patients to access the care and treatments they need, and enable healthcare partners to significantly enhance care quality, effectiveness and value,” said Paul Greenall, Chief Development Officer at Fuze Health. “Combining emerging technologies with the specialized talents of our people, we are committed to delivering next-generation solutions that help our healthcare partners evolve and modernize patient care and treatment in a rapidly changing environment.” SOURCE- Businesswire

Meghalaya Chief Minister Conrad K Sangma presented a Rs 1 crore check to Dr Norman Tunnel Hospital in Jowai today as part of the state's ongoing healthcare improvement efforts. The funding represents the first installment of a larger Rs 2 crore commitment to the hospital under the Meghalaya Health Advancement Policy, which aims to strengthen non-profit healthcare institutions throughout the state. "Dr Norman Tunnel Hospital is the fifth private hospital to benefit from this support, empowering it to continue its vital service to the community," Sangma noted in his social media announcement. This latest disbursement follows a similar Rs 1 crore allocation to Holy Cross Hospital in Tura earlier this month in May, highlighting the government's systematic approach to enhancing medical infrastructure across different regions of Meghalaya. The Chief Minister expressed gratitude to the KJP Assembly and acknowledged the dedication of healthcare professionals at Norman Tunnel Hospital, recognising their contributions to public health in the region. The Meghalaya Health Advancement Policy represents a targeted investment in the state's healthcare delivery system, with particular focus on supporting non-profit institutions that serve communities at the grassroots level. Source: India Today #healthcarestartupindia #dseidehealthcarenetwork

Rajasthan, May 20, 2025: In an inspiring achievement for India’s startup and healthcare landscape, Khet Singh Rajpurohit, co-founder of the fast-rising health-tech platform ClaimBuddy, has been named to the prestigious Forbes 30 Under 30 Asia 2025 list. Featured in the Health & Technology category, Khet is one of only four Indians to be recognized this year—making his inclusion not only a personal milestone, but a symbolic breakthrough for India’s underrepresented health-tech sector on the global stage. ClaimBuddy is transforming how patients and hospitals navigate health insurance, a space long plagued by complexity and delay. The platform leverages technology to streamline the claims process at the point of care—offering patients speed, clarity, and confidence during moments of medical stress. To date, the platform has facilitated over ₹500 crore in insurance claims across 250+ partner hospitals in more than 10 cities. It has also raised $8 million in venture capital funding, including a $5 million Series A round in April 2024 led by Bharat Innovation Fund, with participation from CAC Capital, Chiratae Ventures, and Rebright Partners. Khet’s story is one of perseverance and purpose. Born in the small village of Ghevra in Rajasthan and raised in Ludhiana, Punjab, he worked his way through academic excellence—scoring above 95% in Class 12—and went on to complete his MBA from the Indian Institute of Management (IIM) Bangalore. Forgoing campus placements, he chose the path of entrepreneurship and co-founded ClaimBuddy to tackle the chaos of India’s insurance system at a time when patients need support the most. “This recognition is not just personal—it belongs to every small-town dreamer, every underdog who chooses to solve a real problem with grit, empathy, and technology,” said Khet Singh Rajpurohit. His selection to the Forbes 30 Under 30 list shines a spotlight on the urgent need for innovation in healthcare infrastructure and reinforces the potential for Indian startups to lead globally in digital health transformation. About ClaimBuddy: ClaimBuddy acts as a one-stop solution for health insurance claim assistance for patients and hospitals. The company is building a robust ecosystem to ensure hassle-free insurance claims by leveraging technology and a set of simple yet powerful processes. Source: SugarMint #healthtechstartupindia #dseidehealthcarenetwork

IHH Healthcare’s indirect subsidiary Northern TK Venture Pte Ltd (NTK) has increased its damages claim against Japanese pharma company Daiichi Sankyo Co. about tenfold to ₹11,800 crore or $1.38 billion, over its obstructed open offer for Fortis Healthcare in 2018. NTK has filed an application with the Tokyo District Court to amend its ongoing claim for damages against Daiichi Sankyo, it said on Tuesday. NTK filed a claim in October 2023, seeking damages of 20 billion yen from Daiichi Sankyo for allegedly obstructing its efforts to complete its open offers to acquire shares in Indian hospital chain Fortis Healthcare and its subsidiary Fortis Malar Hospitals. SOURCE-Livemint

New Mountain Capital, LLC (“New Mountain”), a leading growth-oriented investment firm with more than $55 billion in assets under management, today announced a definitive agreement to form Smarter Technologies, the automation and insights platform for healthcare efficiency, created through the strategic combination of portfolio companies SmarterDx, Thoughtful.ai, and Access Healthcare. New Mountain has partnered with and provided strategic growth investments to each of these companies to drive and expand their expertise and capabilities in healthcare revenue management. As a combined entity, Smarter Technologies will bring together these unique strengths, footprints, and offerings to better automate health systems’ workflows and bolster their financial performance. Smarter Technologies serves more than 200 clients, including more than 60 hospitals and health systems, and over 500,000 providers. The company processes more than 400 million transactions and manages over $200 billion in combined revenue annually. Source-Businesswire #SmarterTechnologies #NewMountainCapital #HealthcareInnovation #AIinHealthcare #RevenueCycleManagement #SmarterDx #ThoughtfulAI #AccessHealthcare #HealthcareAI

CureBay, a health-tech startup focused on enhancing rural healthcare access in India, has secured $21 million in a funding round led by Bertelsmann India Investments. This investment underscores the growing interest in innovative health-tech solutions that bridge digital and physical healthcare services. Strategic Expansion and Impact Founded in 2021, CureBay operates a hybrid healthcare model combining technology with a network of eClinics and trained local health workers, known as Swasthya Mitras. This approach has enabled the company to serve approximately 55,000 patients each quarter and enroll 18,000 members in its subscription-based healthcare plans. Currently, CureBay reaches over 18 million people across Odisha and Chhattisgarh, with plans to expand its services to 100 million rural residents across 16 regions in six states, including Jharkhand, Bihar, Uttar Pradesh, and Madhya Pradesh. Technological Advancements The company is developing one of India's largest rural health databases, leveraging AI and data monetization strategies. Through its AI-powered healthcare ecosystem, CureBay Quantum, the platform analyzes rural health trends, enabling targeted outreach and personalized care. Financial Performance CureBay has recorded an eightfold increase in Gross Merchandise Value (GMV) during the first half of FY25 compared to the same period in FY24. The company has reached an Annual Recurring Revenue (ARR) of ₹1,284 million and aims to achieve ₹2,000 million by March 2025. This funding round follows a previous investment of ₹62 crore in January 2024, led by Elevar Equity, which supported CureBay's expansion and technological enhancements. With the new capital infusion, CureBay plans to further expand its network of eClinics, enhance its technological capabilities, and deepen its penetration into underserved markets, reinforcing its commitment to delivering affordable and high-quality healthcare to rural India Source: The Economic Times #healthcarestartupfundingindia #dseidehealthcarenetwork

MedVital, a MedTech startup focused on advanced wound healing and minimally invasive aesthetics, has raised Rs 8.4 crore in a pre-seed funding round led by Nihar Parikh’s 4point0 Health Ventures. The round also saw participation from prominent healthcare and logistics entrepreneurs, including the founders of Tata 1mg, NephroPlus, SafeExpress, Eye Q Hospital, Hexa Health, and AstroTalk. Amid rising cases of chronic wounds due to diabetes, obesity, trauma, and an increasing demand for non-invasive cosmetic treatments, MedVital is addressing a critical gap in accessible, outcome-driven skin repair and restoration technologies. Its flagship product, NoWound, is a compact, digitally enabled, and Made-in-India Negative Pressure Wound Therapy (NPWT) device designed for use in hospitals, clinics, and home-care settings, even in low-resource environments. "MedVital was founded on the belief that skin repair and restoration deserve the same level of innovation as any other medical field,” said Dr. Varun Gupta, Co-Founder and CEO. “We’re building a platform that combines clinically validated devices, intelligent monitoring, and biomaterials to treat complex wounds and restore patient confidence.” The funding will help MedVital expand its product portfolio, strengthen its supply chain, and extend distribution to tertiary hospitals, rural health centres, and home-based care. The company plans to launch liquid chitosan-based wound dressings and enter dermal and hair regeneration segments in the coming months. Co-Founder and COO Tarun Bansal stated, “Our goal is to position India as a global leader in advanced wound care. This funding fuels our mission to deliver practical solutions that work not just in ICUs, but across the entire healthcare ecosystem.” Investor Nihar Parikh added, “MedVital’s integrated approach to chronic wound care and aesthetics aligns with our vision of backing companies solving India’s healthcare challenges through innovation and impact. Their model combines clinical rigour with accessibility—a rare and powerful combination.” Source: bwhealthcareworld #healthcarestartupfundingindia #dseidehealthcarenetwork

Karan Bajaj, the founder of the edtech platform WhiteHat Jr., is back in the startup arena with a fresh venture—this time in healthcare. His new U.S.-based startup, Complement 1, has raised $16 million in a seed funding round to build a personalised, tech-enabled lifestyle coaching platform for cancer patients and individuals at high risk of developing the disease. The round, which was led by Owl Ventures and Blume Ventures, will help the startup scale its coaching infrastructure, enhance its AI-driven personalisation engine, and expand partnerships with cancer centres, health plans, and employers across the United States. It aims to integrate evidence-based interventions—ranging from nutrition and sleep to stress management and physical activity—into the cancer care pathway "Every oncologist will tell you patients need more support incorporating clinically recommended physical activity, nutrition and mind-body practices. We've cracked the code on daily engagement with personalised, compassionate coaching—helping patients make meaningful, lasting improvements during and beyond treatment." Offering one-on-one support Complement1, which is emerging from stealth mode, offers daily one-on-one support through "CoActive Coaches" who deliver customised guidance rooted in clinical research. According to the company, early trial data show that members report 37% fewer treatment side effects, 18% less pain, and 27% better sleep, with adherence rates exceeding 90%. The startup claims that its platform can reduce healthcare costs by up to 30% for cancer patients and high-risk individuals. "Most coaching models rely on a weekly check-in. We meet patients every single day,” said Trupti Mukker, Co-founder and COO of Complement 1. "That daily presence—powered by our CoActive Coaching method—is what creates the trust, accountability, and behaviour change that drive our clinical results. This funding allows us to scale that impact by investing further in our AI systems to ensure consistency, personalisation, and quality at scale. It’s a hybrid approach: high-tech infrastructure matched with high-touch delivery—designed specifically for the complexity of cancer care." "I've seen targeted lifestyle changes transform outcomes—from better energy to reducing recurrence risk," said Dr. Neil M. Iyengar, MD, a leading exercise-oncology researcher and board member of Complement 1. "The challenge has always been getting patients to implement those changes and stick with them. Complement 1's platform provides the intensive support patients need to make sustainable lifestyle shifts, with adherence rates I've never seen before in this field." Source: Indian Startup #healthcarestartupfundingindia #dseidehealthcarenetwork

Cyber threats are increasing, and the healthcare industry is the primary target, putting both patient data and business operations at risk. The Statista report highlights that cyberattacks increased from 60% in 2023 to 67% in 2024, marking the highest level ever recorded. It is essential for all organizations to build strong data security to protect patients’ personal sensitive information and adhere to data privacy compliance. Here are some of the recent attacks that highlight the importance of why you need to protect your patient’s healthcare information: Nearly 190 million individuals lost their data from the recent ransomware attack on the United Health Group, resulting in a financial loss of over $3 billion. Another incident happened with the 2021 Scripps Health, where the ransomware attack caused a monetary loss of $113 million. Security and compliance are no longer an option for the healthcare industry. You need to implement the right security measures that can proactively monitor your patient’s sensitive healthcare information and protect your business from any kind of disruption. In 1996, the U.S. Congress introduced Healthcare Insurance Portability and Accountability (HIPAA) compliance standards to ensure the portability of health insurance coverage and protect the privacy and security of patient health information. Since then, HIPAA has continuously evolved to keep pace with technological advancements and emerging cybersecurity threats. The recent updates to HIPAA 2025 aim to strengthen cybersecurity protection for electronic protected health information (ePHI). Source- Happiestminds #HealthcareCybersecurity #HIPAAComplianc #Cybersecurity2025 #DigitalHealthSecurity #DataPrivacy #HealthTech

Navneet Kaur is a prominent Indian entrepreneur and a leading advocate for women's health and empowerment. As the co-founder and CEO of FemTech India, she has been instrumental in transforming the landscape of women's healthcare in the country. Pioneering FemTech in India Under Kaur's leadership, FemTech India has emerged as the nation's first online repository dedicated to female health technology. The platform serves as a hub for founders, experts, and investors committed to revolutionizing women's health innovation in India. Kaur's vision is to make the femtech market, projected to surpass $100 million by 2025 and serve over 600 million women, both accessible and empowering . Advocacy and Policy Engagement Kaur's influence extends beyond entrepreneurship into policy and global advocacy. In 2023, she represented India at the MedFemTech Congress in Paris, discussing the burgeoning femtech landscape in the country. She also served as a Task Force Member during India's G20 presidency, participating in the G20-DIA Summit in Bengaluru, which focused on driving digital innovation for world economies . Her advisory role with the Department of Women and Child Development in Madhya Pradesh led to contributions to the Ladli Behna Yojana, a government initiative providing monthly sustenance to young women from underserved communities . Media and Community Engagement To foster dialogue and awareness around women's health, Kaur hosts "The FemTech India Podcast," featuring conversations with founders, doctors, public health professionals, policymakers, investors, and researchers. The podcast aims to provide clear, trustworthy information and challenge taboos surrounding women's health issues . Additionally, she launched "The FemTech Coffee Table Book," a first-of-its-kind project highlighting transformative endeavors in the femtech sector, market trends, and groundbreaking solutions. Her weekly newsletter, "FemTech Fridays," keeps subscribers informed about the latest developments in the FemTech ecosystem . Recognition and Impact Kaur's contributions have been recognized internationally. She received the "First in Femtech" award from the U.S.-based platform FemTech Focus, honoring individuals who demonstrate significant contributions to women's health innovation. FemTech India, under her leadership, was voted the best organization for women by an initiative launched by the Economic Times and Femina . Through her multifaceted efforts, Navneet Kaur continues to champion women's upliftment and advocate for affordable, accessible healthcare solutions, making a profound impact on the lives of women across India. Source: Startup News #healthcarestartup #dseidehealthcarenetwork

Shares of Fortis Healthcare demonstrated positive movement during today's trading session, increasing by 2.16% to reach Rs 680.60. This upward trend highlights the stock's activity in the current market environment. Fortis Healthcare is included in the NIFTY MIDCAP 150 index, reflecting its market presence within the mid-cap segment. An analysis of Fortis Healthcare's financial performance provides insights into its revenue, net profit, and EPS trends. The following data is based on consolidated figures. Source-Money Control

Miraqules, a medtech startup from Burdwan, is reengineering emergency bleeding control with StopBleed—a novel, fast-acting nano-biopolymer hemostat designed for hospitals, ambulances, and public use. In a country where road accidents claim nearly 700 lives a day—and excessive blood loss is often the cause—an emergency hemostat could mean the difference between life and death. Miraqules, a medtech startup, has developed StopBleed, a novel nano-biopolymer solution designed to control bleeding rapidly and effectively. The product, first conceptualized as a master’s thesis, is now the centerpiece of a mission to bring critical care closer to where trauma strikes—whether it’s a roadside crash, a battlefield, or a remote clinic. The Founder’s Journey: From Personal Crisis to Public Health Solution The story behind Miraqules is deeply personal. Founder Sabir Hossain grew up in a middle-class family in Burdwan, West Bengal. A traumatic childhood experience—watching his father bleed from an accident without access to proper first aid—left a lasting impression. Years later, while pursuing his master’s in Biomedical Engineering at NIT Rourkela, Sabir began working on biomaterials under Professor Devendra Verma. This academic pursuit soon evolved into a practical mission, culminating in the development of StopBleed. In 2018, Sabir co-founded Miraqules with Dr. Verma and his father. Dr. Mubeen Midda, a junior doctor in Delhi at the time, was drawn into the mission after seeing the product's potential firsthand. By March 2019, he joined full-time, bringing a clinical perspective that grounded the startup’s development in real-world needs. Addressing a Global Health Crisis Uncontrolled bleeding is a leading cause of preventable deaths globally, surpassing diseases like HIV and malaria. In India, roughly 30% of road accident deaths result from blood loss. Existing solutions like tourniquets and pressure dressings are often inadequate or situational. Miraqules(Miracle + Molecules) aims to bridge this gap with StopBleed, a first-response hemostat that is easy to use and effective across a range of settings—from ERs and ambulances to home first-aid kits. Inside the Technology: What Sets StopBleed Apart Unlike conventional hemostats, StopBleed mimics the body’s natural clotting process using a nano-biopolymer that forms fibrin-like threads. It features a 30x higher absorption rate, charge-based clotting acceleration, and atraumatic removal—crucial in emergency care. Designed in multiple formats (powder, gauze, pellets, and patches), the product is adaptable to various types of bleeding injuries, offering frontline responders and clinicians a powerful new tool in trauma management. Market Reach: From Battlefields to Backpacks Currently, Miraqules operates on a B2B and B2G model, planning to sell StopBleed in different formats priced between ₹300 and ₹5000. The long-term goal is to make StopBleed as common in first-aid kits as bandages, enabling bystanders to act before medical help arrives. The potential market is massive. Globally, over 700 million injuries occur annually, with more than 6 million deaths from blood loss. In India alone, 1500 road accidents happen daily. Yet hemostatic products remain scarce at the point of injury. Miraqules is looking to change that by offering a scalable, affordable solution. Achievements, Recognition, and Funding Over the past seven years, Miraqules has raised around $800,000 and secured patents in India, the U.S., and China. A pilot-scale manufacturing facility is in place, and the company is currently conducting human studies at St. John’s Hospital in Bangalore. Miraqules has received support from the Indian Council of Medical Research and won accolades such as the Startup MahaRathi Award and MassChallenge Israel Platinum Winner title. Their recent partnership with the Maharashtra Government will see StopBleed deployed in trauma centers and ambulances, reaching 800 patients as part of a paid pilot. Challenges and the Road Ahead Manufacturing scale-up remains the company’s biggest challenge. Regulatory hurdles and limitations in current bio-incubation facilities mean Miraqules will need to either raise capital to build its own facility or find strategic manufacturing partners. The immediate focus is on completing clinical trials and securing regulatory approvals from India’s CDSCO and the U.S. FDA. By 2026, the startup aims to ship 10,000 units, gain major public health adoption, and begin sales in the U.S. and Indian markets. Long-term goals include serving over 5 million patients and introducing 3–4 new wound care products to transform trauma and surgical care. A Mission Beyond Medicine Beyond saving lives, StopBleed promises to reduce hospital stays, lower transfusion rates, and ease healthcare costs—especially in resource-constrained settings. For Sabir and his team, the product isn’t just about science—it’s about giving people a fighting chance when every second counts. “Startups are consuming,” says Sabir. “Resilience will be more important than hard work. Be obsessed with the problem.” For him, Miraqules is more than a company—it’s a purpose forged from pain and shaped by persistence. Source: YourStory #healthcarestartupindia #dseidehealthcarenetwork

In a significant surge, Indian startups collectively raised approximately $585.71 million this week, marking a substantial increase from the $102.93 million secured the previous week. New Delhi: In a significant surge, Indian startups collectively raised approximately USD 585.71 million this week, marking a substantial increase from the USD 102.93 million secured the previous week. This uptick reflects a growing investor confidence and interest in India's burgeoning startup ecosystem. The majority of this funding was directed towards growth-stage companies, with notable investments including Porter, an on-demand goods transport agency, which secured USD 200 million in its Series F funding round. This round was led by Kedaara Capital and Wellington Management, propelling Porter into the unicorn club. Other significant growth-stage investments encompassed automotive company Routemotic, which raised USD 40 million in its Series C round, and interior design startup Flipspaces, which secured USD 35 million led by Iron Pillar. Additionally, logistics firm Celcius Logistics, foodtech company The Good Bug, and e-commerce startup Blissclub also attracted substantial investments this week. On the early-stage front, 20 startups collectively raised USD 263.41 million. Healthcare company PB Healthcare led this segment with an impressive USD 218 million seed round, backed by General Catalyst. Other early-stage startups that garnered funding include robotics company Posha, edtech firm Footprints, spacetech startup InspeCity, commercial vehicle platform 91Trucks, and proptech company Alt DRX. Geographically, Delhi-NCR-based startups led the funding race with 11 deals, closely followed by Bengaluru with 10 deals. Startups from Mumbai and Chennai also secured investments, indicating a diverse and widespread entrepreneurial activity across the country. Sector-wise, healthtech startups emerged as the most attractive to investors, securing four deals. Logistics and foodtech sectors followed with three deals each, while artificial intelligence, automotive, decor, and robotics sectors also saw investor interest. Meanwhile, in the previous week, the Indian startups had raised approximately USD 102.93 million across 25 deals, with strong contributions from early-stage and growth-stage companies. Bengaluru and Delhi-NCR-based startups led the funding race last week, with seven deals each, followed by Mumbai and Chennai. Source: Economic Times

Swiggy saw its losses almost double in Q4, dragged down by heavy spending on quick commerce. IntegriMedical is eliminating risks associated with traditional injections with its N-FIS technology. Saleswomentoring aims to help women to advance and thrive in sales. Business, it is said, is war without bullets. Amid the tense India-Pakistan conflict, investors are betting big on India’s military prowess, with some defence stocks seeing a double-digit surge on the bourses. Drone maker Ideaforge Technology’s shares hit the upper 20% circuit on Friday. Meanwhile, the shares of Bharat Dynamics, the manufacturer of ammunition and missile systems, rose 5.79% on the NSE as it ramps up production. The Indian financial ecosystem is erring on the side of caution. The Department of Financial Services has asked banks to strengthen their internal systems to deal with any cybersecurity threats, ensure uninterrupted services, and maintain enough cash in ATMs. Also, the Department for Promotion of Industry and Internal Trade has expanded the Credit Guarantee Scheme for Startups, doubling the guarantee cover limit to Rs 20 crore per borrower and increasing the guarantee coverage. From India’s financial landscape to the Vatican’s. The newly elected Pope Leo XIV has a big task ahead of cleaning up the Holy See’s finances, and he may as well use his degree in mathematics. ICYMI: When Pope Leo XIV visited India. Elsewhere, asset management firm Vanguard has pegged Ola parent’s valuation between $1.4-1.5 billion, trimming down the value of its holdings amid rising competition. In today’s newsletter, we will talk about. The cost of Swiggy’s growth Taking the pain out of healthcare Breaking glass ceilings in sales Here’s your trivia for today: Which movie holds the record for featuring the most number of extras? Quick Commerce The cost of Swiggy’s growth Food delivery and quick commerce platform Swiggy saw its losses almost double in the fourth quarter as heavy spending on quick commerce further dragged down the company’s bottom line. Swiggy Instamart, which competes with quick commerce unicorn Zepto and market leader Blinkit, more than doubled its operating revenue to Rs 689 crore, rising for the third consecutive quarter. However, the growth came at a cost, with the segment’s losses widening to Rs 770 crore from Rs 272 crore in the last year and Rs 527 in the previous quarter. Widening losses: Sriharsha Majety-led Swiggy saw its losses widen to Rs 1,081 crore from Rs 553.6 crore in the previous year. On a quarter-over-quarter basis, the company’s losses grew by 35% from Rs 799 crore. During the quarter, Swiggy’s Dineout business turned profitable with earnings of Rs 23 crore, an improvement from a loss of Rs 8 crore in the previous quarter. Additionally, the company is evaluating a potential shift to an inventory-led model for its quick commerce arm but is unlikely to make an inorganic move in the near term, according to group CFO Rahul Bothra. Source: YourStory #healthcarestartupindia #dseidehealthcarenetwork

Founded in 2020, IntegriMedical is a healthcare technology company on a mission to revolutionize drug delivery by eliminating the fear, discomfort, and safety risks associated with conventional needle-based injections. For millions across the globe, the sight of a needle is enough to induce anxiety, especially in children. Yet, needle-based injections remain the dominant method of drug delivery—even as safer, more comfortable alternatives have begun to emerge. But one Pune-based med-tech startup is working to take the dread out of necessary injections. Founded in 2020 by Sarvesh Mutha, Ankur Naik, Scott McFarland, and Mark Timm, IntegriMedical is on a mission to reimagine how medications are delivered. Their answer: a needle-free, spring-driven device that administers drugs through the skin using a high-pressure jet, minimizing trauma and eliminating the risks associated with traditional injections. Born from firsthand experience The idea for IntegriMedical was rooted in founder Sarvesh Mutha’s experience in the healthcare and medical device industries. “Needle phobia is more than just fear—it can cause patients to skip life-saving treatments,” says Mutha, now the company’s Managing Director. The issue also extends to healthcare workers, who are routinely exposed to needle-stick injuries and the risks of cross-contamination. Determined to develop a safer alternative, Mutha joined forces with co-founders Ankur Naik—an expert in device design and regulatory compliance; Scott McFarland—a healthcare veteran with deep experience in finance and delivery; and Mark Timm—a seasoned entrepreneur in global supply chain operations. “Together, we envisioned a future where drug delivery would be painless, sustainable, and more accessible,” says Mutha . Painless injection process The Needle-Free Injection System (N-FIS) is built around a stainless-steel piston mechanism that delivers medications intramuscularly or subcutaneously in under a tenth of a second. “Instead of a needle, the device uses a disposable cartridge with an orifice finer than a strand of human hair to create a precise jet stream. The result is a nearly painless experience that also reduces the risk of cross-contamination, tissue damage, and hazardous medical waste,” explains Mutha. The Pune-based startup received CDSCO approval for N-FIS in December 2022 and launched it commercially in April 2024 after pilot testing. The device is backed by regulatory approvals including CE, ISO 13485, and MDSAP, and is protected by a US patent. Source: YourStory #healthcarestartup #dseidehealthcarenetwork

Carta Healthcare, a leading provider of AI-powered clinical data abstraction, today announced it has secured $18.25 million in Series B1 financing. This investment will accelerate the company's growth as demand surges among health systems and life sciences organizations for AI-driven innovation that transforms clinical data into valuable insights. The investment was led by UPMC Enterprises, with participation from new strategic investors, including MemorialCare Innovation Fund, Rex Health Ventures (the investment fund for the UNC Health), Tampa General Hospital Ventures and support from existing investors Memorial Hermann Health System, Frist Cressey Ventures, Storm Ventures, Paramark Ventures, CU Healthcare Innovation Fund, and Mass General Brigham Ventures. "UPMC Enterprises invests in companies that are solving real problems in healthcare delivery," said Brent Burns, executive vice president at UPMC Enterprises, the innovation, commercialization and venture capital arm of UPMC. "Health systems face significant challenges associated with clinical data abstraction and patient trial matching, which are time-consuming, labor-intensive processes. Carta Healthcare leverages AI to streamline data abstraction and provide analytics that clinicians can use to improve patient care. We look forward to partnering with Carta Healthcare to advance their mission and explore opportunities to implement their solutions across our health system." The new funding will enable Carta Healthcare to further expand its growing customer footprint, particularly in the life sciences market, following the late 2024 acquisition of Realyze Intelligence from UPMC Enterprises. Realyze Intelligence's technology leverages AI to rapidly analyze structured and unstructured data and identify specific patients that match clinical trials and other research studies. "We have long recognized that better clinical data abstraction and activation is integral to improving healthcare," said Navid Farzad, Managing Partner at Frist Cressey Ventures. "Since our initial investment, Carta has been laser focused on solving this challenge for health systems by using the Carta Healthcare AI platform to automate the data abstraction process, generating high-quality clinical data while simultaneously realizing an immediate ROI by reducing the high labor cost of data abstraction." SOURCE- PR Newswire #CartaHealthcare #FundingNews #SeriesB1 #HealthTech #AIinHealthcare #ClinicalData #HealthcareInnovation #DigitalHealth #HealthIT #MedTech #ClinicalAnalytics #HealthAI #StartupFunding #DataAbstraction #HealthcareAI #VentureCapital #HealthcareStartup

A digital revolution is sweeping through the pharmaceutical industry, and it’s powered by artificial intelligence (AI). From automating drug discovery to making clinical trials more efficient and driving breakthroughs in biotechnology, AI is reshaping the healthcare landscape. And India, long known as the ‘pharmacy of the world, is positioning itself to ride this wave of innovation, as it should! India’s pharmaceutical sector has always been a global heavyweight. As the world’s third-largest producer of drugs by volume, it has historically focused on affordable generics. But now, with the infusion of AI-driven capabilities, the industry is shifting gears—becoming a hub of R&D, innovation, and precision medicine. As per a EY-Pantheon and Microsoft report that tracked the sector, AI market in pharmaceuticals is projected to hit USD16.49 billion by 2034 and AI-driven medical devices are set to grow to USD97.07 billion globally by 2028. India must move quickly and decisively to gain the necessary advantage and leverage. Major Indian pharmaceutical firms such as Sun Pharma, Dr Reddy’s Laboratories, and Cipla are investing heavily in AI technologies. Their goal: reduce the spiralling costs and timeframes associated with developing new drugs, and leapfrog into the realm of novel therapeutics. Meanwhile, India’s homegrown AI startups are gaining momentum by offering specialised solutions across the pharma value chain. Companies like Qure.ai, Indegene, and AIRA Matrix are helping digitise diagnostics, streamline clinical trial processes, and ensure regulatory compliance through advanced analytics and automation. Qure.ai, for example, has developed deep learning algorithms capable of interpreting complex medical images like X-rays and CT scans. These tools are not only helping doctors make faster and more accurate diagnoses but are also being integrated into clinical trial pipelines to identify suitable patient cohorts. Indegene, on the other hand, supports pharma companies in managing large datasets and enhancing patient engagement using AI-powered systems—bringing a new level of precision to the business side of medicine. Source: millenniumpost #healthcarestartup #india #dseidehealthcarenetwork

With policy backing and shifting global supply chains, India’s medtech industry is poised to emerge as a global manufacturing and innovation hub. India’s medtech industry is undergoing a dramatic transformation, propelled by shifting global trade dynamics, rising income levels, breakthrough innovations, and a renewed push for localisation. Once seen merely as a sales destination for global medtech giants, India is now positioning itself as a serious contender to become a global hub for innovation, manufacturing, and healthcare research. Driving this transformation is a confluence of factors: the cost competitiveness of Indian healthcare, a burgeoning middle class with growing health consciousness, the government’s production-linked incentive (PLI) scheme, and a policy push to develop a robust domestic medtech ecosystem. With rising domestic demand and a favourable business environment, India is attracting multinational players eager to tap into both its market and talent pool. India has become an increasingly attractive destination for global healthcare consumers, offering high-quality medical care at a fraction of the cost in developed countries. This cost arbitrage, along with a deep pool of skilled professionals and robust tertiary care infrastructure, has made India a magnet for medical tourism. Multinational corporations such as Siemens Healthineers and Philips are taking note. Siemens is investing Rs 91.9 crore in local manufacturing of advanced diagnostic imaging systems such as CT and MRI machines at its Bengaluru facility. Additionally, the company is building an integrated campus with a projected investment of Rs 1,910 crore. Philips, too, is doubling down on its ‘Make in India’ initiative, having invested around Rs 750 crore over recent years. Source: policy circle #healthcarestartupfunding #dseidehealthcarenetwork

HCA Healthcare, Inc. (NYSE: HCA) has announced its participation in the upcoming Bank of America 2025 Healthcare Conference. The presentation is scheduled for May 13, 2025, at 9:20 AM PT. Investors and interested parties can access the live audio webcast and related presentation materials through the Investor Relations section of the company's website at www.hcahealthcare.com. Please note that dates and times are subject to change; for the latest information, refer to the conference schedule or the Investor Relations section of the company's website. HCA Healthcare is a leading provider of healthcare services in the United States, operating 192 hospitals and approximately 2,500 ambulatory sites of care across 20 states and the United Kingdom. The company is headquartered in Nashville, Tennessee. SOURCE- Business Wire #HCAHealthcare #HealthcareConference #MedicalInnovation #HealthcareLeadership #InvestingInHealthcare #HealthcareServices #BankOfAmericaHealthcare #HCA2025 #HealthcareIndustry #HealthTech #InvestorRelations #MedicalCommunity

InvAscent, a healthcare-focused private equity firm, has announced the final close of its fourth fund, India Life Sciences Fund IV (ILSF IV), at $305 million. Although this falls short of its initial target, the fund continues InvAscent's commitment to investing in India's life sciences sector. Strategic Investments from ILSF IV Since its inception, ILSF IV has been actively deploying capital across various segments of the healthcare industry: Maiva Pharma: In May 2024, InvAscent, in partnership with Morgan Stanley Private Equity Asia, invested INR 1,000 crore (~$120 million) in Maiva Pharma, India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds are earmarked for establishing a new manufacturing facility near Hosur, enhancing Maiva's capabilities in sterile dosage forms, including pre-filled syringes and oncology injectables. Geri Care Health Services: In January 2025, InvAscent led a ₹110 crore (~$13 million) funding round in Geri Care, India's pioneer in integrated geriatric care. The investment aims to expand Geri Care's services across key Southern Indian cities, including Bengaluru, Hyderabad, Kochi, and Coimbatore. ABI Health Technologies: In December 2023, InvAscent invested $10 million in ABI Health Technologies, a Bangalore-based health-tech SaaS company. ABI's flagship product, ClaimBook, automates hospitals' health insurance claims management processes and has been implemented in over 300 hospitals across India. InvAscent's Track Record Founded in 2005, InvAscent has established itself as a leading investor in India's life sciences sector. With assets under management exceeding $800 million, the firm has invested in over 35 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech industries. The successful close of ILSF IV, despite falling short of its target, underscores InvAscent's sustained commitment to fostering growth and innovation in India's healthcare landscape. Source: dealstreetasia #healthtechstartup #dseidehealthcarenetwork

Indian startups have recently secured approximately $103.2 million in funding, highlighting a robust interest from investors across various sectors. This influx of capital underscores the resilience and adaptability of India's startup ecosystem, even amidst global economic uncertainties. Key Funding Highlights Artificial Intelligence & Robotics: Pune-based AI and robotics startup Haber raised $38 million in a round led by Creaegis, with participation from Accel India and BeeNext Capital. This investment aims to advance AI-driven automation solutions, particularly in industrial automation—a sector ripe for disruption as companies seek efficiency and productivity gains. SaaS & Digital Health: Spry Therapeutics, a Pune-based SaaS company, secured $15 million in a round led by Flourish Ventures, with participation from existing investors Together Fund, Fidelity’s Eight Road Ventures, and F Prime Capital. The funding will accelerate Spry's growth in offering digital healthcare solutions, reflecting growing investor interest in tech solutions for healthcare. Biotech & Agritech: BioPrime, a biotech startup, raised $6 million in a round led by Belgium-based Edaphon. The funding, supported by existing investors Omnivore and Inflexor Ventures, will enable BioPrime to further develop its biotechnological solutions, particularly in agriculture and food security—two areas critical to addressing global sustainability challenges. Sectoral Trends The recent funding activities indicate a strategic shift towards sectors with long-term growth potential: Fintech: Continues to be a dominant sector, with significant investments reflecting the ongoing digital transformation in financial services. Enterprise Tech: Startups focusing on B2B solutions are attracting substantial funding, emphasizing the demand for innovative enterprise technologies. E-commerce: Despite a general slowdown, the sector remains active, with startups securing funds to enhance their platforms and customer reach. Outlook The infusion of $103.2 million into Indian startups signifies a positive trajectory for the country's innovation landscape. With investors showing confidence in sectors like AI, SaaS, biotech, and agritech, Indian startups are well-positioned to drive technological advancements and contribute significantly to the global market. Source: Munsif news #healthcarestartupfunding #dseidehealthcarenetwork

Manipal Hospitals, IHH Healthcare, and Blackstone-owned Quality Care India are among the frontrunners vying for Sahyadri Hospitals, Maharashtra's largest hospital chain, with bids ranging from ₹4,500-5,000 crore. Ontario Teachers’ Pension Plan Board is divesting the chain amid a wave of PE-led consolidation in India's rapidly growing healthcare sector, which is witnessing significant investment and expansion. Manipal Hospitals, Singapore’s IHH Healthcare, Blackstone-owned hospital chain Quality Care India, Max Healthcare, KKR & Co. and EQT Partners are among those that have submitted initial bids for Sahyadri Hospitals, said people aware of the matter. The bids are in the range of Rs 4,500-5,000 crore, they said. Sahyadri, Maharashtra’s largest hospital chain, is owned by Canada's Ontario Teachers’ Pension Plan Board. SOURCE-THE ECONOMIC TIMES #SahyadriHospitals #HealthcareNews #HospitalAcquisition #ManipalHospitals #IHHHealthcare #EQTPartners #HealthcareInvestment #PrivateEquity #MergersAndAcquisitions #IndianHealthcare #HealthcareBusiness

In an ecosystem where venture-backed direct-to-consumer (D2C) startups frequently chase scale at the expense of sustainability, Powerhouse91 has quietly emerged as a high-efficiency outlier. The roll-up e-commerce brand aggregator has crossed a major milestone: achieving INR 100 crore in annual recurring revenue (ARR) and turning EBITDA profitable as of April 2025, all with a modest USD 2.5 million (~INR 21.15 crore) in total funding. Founded in early 2022 by Aqib Mohammed and Shashwat Diesh, Powerhouse91 exemplifies a new wave of digital-first consumer brand builders focused on operational rigor, financial discipline, and category depth rather than blitzscaling. The company runs two core brands: Azah: A feminine hygiene and wellness brand. Slovic: Focused on fitness and lifestyle products. According to some reports, the startup processed approximately 2.4 lakh orders in March 2025 alone, predominantly via online channels including Blinkit, Zepto, and Amazon. Monthly order volumes continue to grow at a healthy double-digit rate, signaling robust consumer traction. EBITDA Breakthrough with Frugality at Core Powerhouse91’s path to profitability is particularly noteworthy in a funding environment where burn-heavy D2C models have faced increased investor scrutiny. While many roll-up startups raised large venture rounds in their early stages, Powerhouse91 has managed to scale sustainably with just USD 2.5 million from investors including Titan Capital, FJ Labs, Crossbeam Venture Partners, and Mamaearth’s co-founder Varun Alagh. The company has not raised funds in nearly four years. The company achieves EBITDA profitability by April 2025, despite posting a INR 4 crore EBITDA-level loss in FY25 and INR 5.97 crore in losses on INR 40 crore revenue in FY24. The turnaround demonstrates the startup’s strong margin improvement and cost-control efforts over the past year. Source: ipocentral #healthcarestartupfunding #dseidehealthcarenetwork

IIIT Bhopal Gets Govt Funding For AI Healthcare, Research Bhopal (Madhya Pradesh): Indian Institute of Information Technology (IIIT) Bhopal has secured four prestigious research projects under central government’s Partnerships for Accelerated Innovation and Research programme, administered by the Anusandhan National Research Foundation (ANRF). Working in association with IIT Indore as hub institution, IIIT Bhopal will contribute to national research initiatives in the critical domains of Healthcare and Medical Technology and Advanced Materials. The institute’s proposals were selected through a rigorous, multi-stage national evaluation conducted by ANRF at Indian Academy of Sciences, Bengaluru, on March 7-8, 2025. Source: Free Press Journal #healthcarefunding #dseidehealthcarenetwork

Private hospital chain Max Healthcare plans to invest Rs 6,000 crore over the next three years to expand its network across key locations in India, its chairman and managing director, Abhay Soi, told ET on Tuesday. Soi said the hospital chain, which is entering its 25th year, will add three more facilities this year to mark the milestone. At present, Max Healthcare operates 22 healthcare facilities with around 5,000 beds "We have a total of 22 hospitals right now. This is our 25th year and also year 2025, so we want to expand it to 25 hospitals in the country," he said, adding that the company is looking at a 400-bed hospital in Saket, expansion in Nanavati and Mohali, and a new hospital in Gurugram by December this year. On Tuesday, health minister JP Nadda inaugurated a 300-bed greenfield facility of Max Super Speciality Hospital at Dwarka. The new facility will have more than 120 critical-care beds, 10 modular operation theatres and advanced cath labs. SOURCE- THE Economic Times #MaxHealthcare #HealthcareExpansion #HealthcareNews #IndianHealthcare #HospitalGrowth #HealthcareInvestment #MedicalInfrastructure #HealthcareInnovation #HealthcareBusiness #HealthcareDevelopment #HealthSectorIndia #HospitalNetwork #HealthcareIndustry #HealthTechIndia

Care.fi, a healthcare-focused fintech startup, has raised Rs 6 crore in debt funding from RevX to deepen its involvement in the Ayushman Bharat scheme. The Gurugram-based startup plans to deploy the capital to strengthen its platform's ability to support hospitals participating in the rapidly expanding national health scheme. The funding comes as the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) broadens its reach. As of June 2024, the programme covers over 550 million beneficiaries and counts more than 29,000 empanelled hospitals, making it the world's largest health assurance initiative. Founded in 2021 by Sidak Singh and Vikrant Agrawal, Care.fi offers tech-enabled financial solutions to healthcare providers, including hospitals, doctors, and allied suppliers. The startup claims to have disbursed over Rs 800 crore to more than 100 healthcare institutions and has secured a Non-Banking Financial Company (NBFC) licence within just two years of operations. “Our focus has always been to ease the burden of operational and financial processes for healthcare providers," said Sidak Singh, Co-founder of Care.fi. "With the Ayushman Bharat scheme becoming more centralised and 60% of hospital revenue now coming from insurance schemes, our solutions can seamlessly plug into this evolving framework and help hospitals manage claims and cash flows more effectively.” Vikrant Agrawal, Co-founder of Care.fi, added, “This infusion from RevX will not only allow us to scale our operations but also enable better support for hospitals onboarded under the Ayushman Bharat initiative. We see this as a powerful step toward building a resilient and inclusive healthcare financing ecosystem in India.” Source: Indian startup news #healthcarestartup #startupnews #dseidehealthcarenetwork

The Union government recently announced that the National Eligibility-cum-Entrance Test (NEET) will be made mandatory for admission to physiotherapy and other allied health courses under a newly introduced competency-based curriculum. This move is said to be a part of a comprehensive overhaul of 10 professional programmes. On April 23, the Union Health Ministry, alongside the National Commission for Allied and Healthcare Professions (NCAHP), unveiled the updated curriculum. According to a press release, the revised curriculum seeks to establish "consistency in educational content and delivery," and is set to be implemented across the country from 2026. Among the 10 courses with revised curricula, five (physiotherapy, nutrition and dietetics, optometry, dialysis therapy, and medical radiology and imaging technology) will now require students to appear for NEET to gain admission. This move has sparked concern among educationists and professionals in the allied health sectors. PB Prince Gajendra Babu, educationist and general secretary of the State Platform for Common School System-Tamil Nadu (SPCSS-TN), criticised the decision, calling it a slow push to bring allied medical courses under the umbrella of NEET. SOURCE- The News Minute #NEET #physiotherapy #alliedhealth #healthcare

Technology is reshaping healthcare in India, creating new opportunities for those interested in careers at the intersection of medicine, data, and innovation. From AI specialists to clinical analysts, a new wave of roles is e merging. The convergence of technology and healthcare is affecting how medicine is delivered in India. Healthcare is undergoing a major transformation, opening up diverse career opportunities for students and professionals interested in medicine, technology, and management. As healthcare systems evolve, new roles emerge at the intersection of clinical practice, research, data management, and technology, offering a wide range of options beyond traditional medical professions. 1. HEALTH INFORMATICS SPECIALIST Health informatics can be defined as the application of science and the art of data assessment and management concerning health information using digital tools. Health informatics specialists work with EHRs, patient information repositories, and analytics platforms to optimise care effectiveness. Hospitals, insurance companies, and health-tech startups need health informatics specialists to help integrate services and make sense of healthcare data. 2. BIOMEDICAL ENGINEER Biomedical engineering is primarily concerned with the design, manufacture, and maintenance of medical devices, and biomedical engineers in India are in high demand as the demand for low-cost, locally-made medical devices increases along with innovation in prosthetics, diagnostic devices, and complementary devices that detect human digital health. 3. CLINICAL DATA ANALYST Healthcare's digital transformation has produced massive amounts of health data. Clinical data analysts help organisations make sense of data to improve treatment for patients and workflow efficiency to enhance patient experience. They analyse trends, assess treatment performance, and support clinical trials. 4. DIGITAL HEALTH ENTREPRENEURSHIP Many professionals are forging their careers and embarking on entrepreneurial journeys by launching startups in the area of fitness applications, mental health platforms, or remote monitoring. India is making progress towards creating an ecosystem that supports digital health innovation through government policies like the National Digital Health Mission (NDHM). 5. AI AND MACHINE LEARNING SPECIALIST/HEALTHCARE Artificial intelligence is changing how we think about disease prediction, diagnosis and even drug discovery. AI and machine learning specialists are working in this niche to create algorithms to read X-rays, pathologists' slides, or predict risk in healthy individuals. Source: India Today #healthcarestartupfunding #startup #dseidehealthcarenetwork

The National Commission for Allied and Healthcare Professions (NCAHP) on Wednesday announced that physiotherapists can now use the ‘Dr’ title as a prefix and ‘PT’ as a suffix to their names. The decision came as part of the launch of the 2025 Physiotherapy Curriculum by the NCAHP under the Union Ministry of Health and Family Welfare. Welcoming the move, Mumbai-based Dr Zita Misquitta (PT) said, “For the first time, patients nationwide can directly access physiotherapy services without needing a referral. Standardised education and clinical training mark a new era of professionalism and credibility. This isn’t just a regulatory update – it’s a turning point in India’s healthcare narrative. Physiotherapists are no longer working in the shadows of other medical professionals. They are stepping forward, not just as healers of the body, but as independent practitioners shaping a healthier tomorrow.”

PB Fintech, the parent company of Policybazaar and Paisabazaar, has made a significant investment of Rs 539.4 crore in its newly formed healthcare subsidiary, PB Healthcare Services Private Limited. The investment marks the first tranche of a larger seed funding round worth Rs 1,461.6 crore, which includes contributions from both PB Fintech and external investors. The funding was approved earlier through a shareholder postal ballot. The investment was completed on April 24 through the subscription of 5.39 crore Compulsory Convertible Preference Shares at Rs 100 per share. With this infusion, PB Fintech’s stake in the healthcare subsidiary will drop from 100% to 32.14% on a fully diluted basis. The strategic dilution is intended to attract external capital and includes the creation of an Employee Stock Option Plan to attract and retain top talent in the healthcare space. In a statement, PB Fintech emphasised that the investment is designed to strengthen PB Healthcare's financial foundation and support its ambitious growth goals. Establishing hospitals The subsidiary, incorporated in January 2025, plans to establish hospitals with a capacity of up to 1,000 beds in its first year, offering managed healthcare services tailored to Policybazaar's customer base. The move represents a significant diversification for PB Fintech, whose primary businesses have been in digital insurance and lending. The company sees healthcare as a natural extension of its services and a growing opportunity in India's underserved medical infrastructure landscape. PB Healthcare was established to operate in the healthcare and allied services space and is headquartered in Gurugram. It currently has an authorised capital of Rs 2,500 crore but has yet to report turnover, given its recent incorporation. Financial performance PB Fintech reported strong financial results in the December quarter of FY25, with revenue growing 48% year-on-year to Rs 1,292 crore and net profit rising to Rs 72 crore from Rs 37 crore a year ago. The healthcare investment is expected to build on this momentum and broaden the company's service ecosystem in the Indian market. Source: indianstartupnews #healthcarestartup #startupfunding #dseidehealthcarenetwork

Investor interest in India’s healthcare and pharmaceutical landscape remains resilient, with strong momentum in health tech. According to the Grant Thornton Bharat Pharma & Healthcare Dealtracker, Q1 2025 recorded 71 deals amounting to $2.6 billion, reflecting a slight 5% dip in volumes and a significant 69% drop in values compared to Q4 2024. Despite the moderation in deal values, investor interest in the healthcare and pharmaceutical sector remains resilient. M&A activity contributed 57% of the total deal value, while private equity drove 59% of the overall volume. Excluding IPOs and QIPs, the quarter saw 67 deals valued at $2.1 billion—a marginal 3% decline in volumes and a 70% drop in values, primarily due to the absence of the $5 billion Aster DM Healthcare–Quality Care India merger that skewed the previous quarter’s numbers. Adjusting for this outlier, Q1 2025 saw a 15% increase in deal values. On a year-on-year basis, volumes rose by 34% and values surged by 326%. The quarter also saw a rise in high-value deals (≥ $100 million), with six such transactions—double that of the previous quarter—indicating robust investor confidence and a continued appetite for scale investments. The largest M&A deal of the quarter was Intas Pharmaceuticals’ $558 million acquisition of Udenyca from Coherus Biosciences, accounting for nearly 27% of total sector values and signaling India’s growing ambitions in the US biosimilars space. Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics further emphasized ongoing consolidation in oncology. Private Equity (PE) activity remained concentrated in early-stage (≥ Series A) funding, with health tech leading the charge, followed by the wellness segment, particularly in sexual wellness and nutritional products. The top five PE deals accounted for 74% of total PE value, with the largest being Kotak Alternate Asset Managers’ $121 million investment in Tirupati Medicare Pvt Ltd. Q1 2025 saw three IPOs raising $503 million and one QIP worth $74 million, spanning hospitals, medical devices, and pharma.

The healthcare system offers wide-ranging innovative and friendly healthcare to senior citizens in 38 community health centres and 10 hospitals serving hundreds of thousands of citizens a year. Show Chwan Healthcare System, led by the founder Dr Minho Huang and the CEO Dr Janet Huang, stands as one of the most unique comprehensive non-public, non-profit healthcare corporations in Taiwan and Asia, which has offered tertiary medical services combined with extensive community health services for more than five decades. The healthcare system currently includes 10 hospitals, with four tertiary and six secondary district hospitals, as well as two high-end hospitals for oncology and traditional complementary medicine. It also boasts the Asia Institut de Recherche contre les Cancers de l'Appareil Digestif, or iRCAD, a world-class microsurgery training centre that has provided advanced hands-on training for more than ten thousand clinicians in more than 50 countries worldwide. Show Chwan also provides wide-ranging community primary services for senior citizens in 38 community health centres, which take care of more than ten thousand seniors a year, with a few in-house nursing homes for more than 500 citizens. These services, fit with easy accessibility by regular shuttle buses, and home care services, are well recognised for their community-friendly services. SOURCE- Healthcare Asia Magazine #ShowChwanHealthcare #InnovativeMedicine #TaiwanHealthcare #GlobalHealthExcellence #AdvancedMedicalCare #HolisticHealing #MedicalInnovation #ShowChwanHospitals #CuttingEdgeTreatment #HealthcareLeadership

Union Health Minister J P Nadda has said that providing affordable and quality healthcare to every poor person in the country is a priority of the central government. Mr Nadda said this while chairing a breakaway session titled “Promoting Swasth Bharat through Ayushman Bharat PM Jan Arogya Yojana and Ayushman Arogya Mandir” during the Civil Services Day celebrations in New Delhi today. Mr Nadda highlighted that the government’s expenditure on healthcare has increased from 29 percent in 2014 to 48 percent now, leading to a decline in out-of-pocket expenditure for people. He stated that the screening of communicable and non-communicable diseases in Ayushman Arogya Mandir and expanding the package of services has helped in providing preventive and promotive healthcare. The health minister said that health facilities are being encouraged to undertake self-assessment under the Indian Public Health Standards 2022 and National Quality Assurance Standards. He stated that while there has been tremendous progress in healthcare in the last 10 years, the government is committed to providing affordable, accessible, equitable and quality healthcare for all. Speaking on the occasion, Member, Health, NITI Aayog, Dr V K Paul, highlighted that due to the implementation of AB PMJAY, the out-of-pocket expenditure has decreased from 64 percent in 2013-14 to 39.4% in 2021-22. SOURCE- News on air #AffordableHealthcare #QualityHealthcare #HealthcareForAll #HealthForAll #JPNadda #IndiaHealthMission #AyushmanBharat #PublicHealth #GovernmentInitiative #DigitalHealthIndia #HealthyIndia #HealthcareReforms #IndianHealthcare

​The Dubai Chamber of Commerce has inaugurated a new office in Bengaluru, underscoring its commitment to strengthening ties with India's technology and artificial intelligence (AI) sectors. This strategic expansion reflects Dubai's broader initiative to diversify its economy and establish itself as a global digital hub.​ Bengaluru: A Strategic Choice Bengaluru, often referred to as the "Silicon Valley of India," boasts a robust tech ecosystem. The city is home to over 2,000 IT companies and contributes more than one-third of India's total IT exports . Furthermore, it houses over 40% of India's Global Capability Centers (GCCs), making it a pivotal location for multinational corporations seeking innovation and technological advancement .​ Dubai's Vision for Digital Collaboration Dubai is actively transitioning from its traditional oil-based economy to a diversified digital economy. The emirate aims to double the digital economy's contribution to its GDP from 9.7% in 2022 to over 20% by 2031 . Initiatives like the Dubai AI Campus, the largest AI cluster in the Middle East and North Africa, exemplify this commitment .​ The UAE-India Comprehensive Economic Partnership Agreement (CEPA), effective since May 2022, further facilitates collaboration in emerging sectors such as AI, blockchain, and fintech . The new Bengaluru office is poised to serve as a conduit for Indian tech startups and enterprises aiming to tap into Dubai's burgeoning digital landscape.​ The establishment of the Dubai Chamber's office in Bengaluru offers Indian tech companies enhanced access to Dubai's resources, including funding opportunities and a supportive regulatory environment. This move is anticipated to foster increased collaboration, innovation, and growth for Indian enterprises in the global digital arena.​ For Indian tech entrepreneurs and startups, this development presents a significant opportunity to engage with Dubai's dynamic digital economy and expand their global footprint. Source: Deccan Herald #healthcarestartupnews #dseidehealthcarenetwork

Healthtech startup Risa Labs has raised $3.5 million in a seed funding round led by Flipkart co-founder Binny Bansal. The round also witnessed participation from Oncology Ventures, General Catalyst, z21 Ventures, Odd Bird VC, and angel investor Ashish Gupta. The proceeds will be used to deploy its AI-based automation platform across 100 cancer centers in the US over the next two years, Risa Labs said in a press release. Co-founded in 2024 by Kshitij Jaggi and Kumar Shivang, Risa Labs offers a workflow orchestration platform called BOSS (Business Operating System as a Service). The system uses a network of AI agents, including large language models and digital twins, to automate administrative processes by breaking down complex workflows into micro tasks. Risa Labs weeds out the problems of delaying life-saving treatments due to manual and error-prone workflows. Prior authorisation requirements are a key contributor, with 70% of patients facing delays and a third waiting up to a month — a lag that can increase mortality risk in certain cancer types. Risa Labs claims that BOSS has already been deployed at a cancer center in the US, where it reduced prior authorisation times from 30 minutes to under five, processed over $1 million in medications, and cut administrative costs by two-thirds. Risa aims to extend its platform across multiple nodes of the oncology ecosystem, enabling greater coordination and intelligence among providers, life sciences organisations, and other stakeholders as the company aims to build a unified layer for AI-driven orchestration throughout the drug lifecycle. Source- Entrackr #StartupFunding #RisaLabs #BinnyBansal #SeedRound #IndianStartups

Tulu Health, a pioneering healthtech and fintech startup founded by experts from AIIMS, IIT, and Stanford, has launched India’s first AI Agent Platform aimed at transforming patient experiences and streamlining hospital operations. Officially unveiled on April 12 at Pullman Aerocity, Delhi, the platform integrates modular AI agents with WhatsApp and hospital websites—making digital health services more accessible, personalised, and user-friendly. “Tailored for Hospitals, Built for Patients,” the platform is designed to eliminate friction in the healthcare journey. With support for multiple languages and mobile optimisation, it ensures that even users with low digital literacy can access AI-powered assistance without needing to download new apps. Dr. Adil, Founder of Tulu Health, said, “We built Tulu to meet patients where they are—on WhatsApp, in their language, with zero friction. This isn’t just a tool; it’s a transformation in how India experiences healthcare.” A former AIIMS doctor and Stanford India Biodesign fellow, Dr. Adil emphasised how Tulu addresses challenges like lack of care continuity, high out-of-pocket costs, and post-discharge gaps. This is his second healthtech venture, following a BIRAC-funded startup incubated at IIT Delhi. Tulu’s platform supports hospitals by expanding patient reach, enhancing care flow, and automating workflows through white-labeled AI agents that plug into systems like EHR, CRM, ERP, and WhatsApp. Patients benefit from AI-assisted decision-making, cashless support for pre- and post-hospitalisation (up to 180 days), and real-time access to financial options. Advanced tech—such as generative AI, NLP, and deep learning—powers the solution, developed in-house with support from global partners like OpenAI and Anthropic. Dr. Vijay Agarwal, President of the Consortium of Accredited Healthcare Organisations, praised Tulu’s AI-driven pre-surgery consent and education tools, saying, “Tulu represents a great hope for the future of healthcare: collaborative, compassionate, and innovative.” Akif, Advisor to Tulu Health and ex-Innovaccer leader, added, “Tulu’s AI agents offer human-centered design at scale. The monetisation model through hospital-linked marketplaces is a breakthrough.” Tulu Health is onboarding hospital networks, state governments, and NBFCs for pilot projects. It’s also in discussions with leading public health bodies like AIIMS, GTB Hospital, and LNJP for broader rollout. With a B2B2C model, SaaS subscriptions, and transaction-linked revenue streams, Tulu aims to become a global AI agent marketplace. The startup is well-positioned to lead India’s push into Agentic AI, with Deloitte reporting that 80 per cent of businesses are exploring autonomous agent solutions. Source: bwhealthcareworld #healthcarestartup #AI

The India Artificial Intelligence market has experienced tremendous growth in recent years, positioning itself as a global leader in artificial intelligence (AI) innovation and adoption. With advancements in smart technology solutions, AI is now reshaping industries such as healthcare, finance, education, and more. This transformative shift is driven by the increasing availability of big data, improvements in computational power, and a growing ecosystem of startups and tech companies pushing the boundaries of AI capabilities. India is quickly emerging as a hub for AI development due to its unique combination of technological prowess, a large talent pool, and a booming startup ecosystem. The AI market in India is expected to witness significant expansion, providing vast opportunities for businesses to enhance operations, improve efficiency, and drive innovation. Artificial intelligence has brought about notable changes in India's healthcare sector, enhancing patient care and improving the efficiency of medical services. AI-powered systems are helping medical professionals in diagnosing diseases more accurately, recommending treatment plans, and predicting patient outcomes with advanced data analytics. These AI solutions in healthcare are enabling faster decision-making, reducing errors, and optimizing hospital management. A prime example of AI's role in healthcare is its application in medical imaging and diagnostics. AI algorithms analyze medical images, such as X-rays, CT scans, and MRIs, to detect signs of diseases like cancer or neurological disorders. This can lead to earlier detection, which is crucial for improving patient outcomes. Moreover, AI is playing a pivotal role in personalized medicine. By analyzing a patient's genetic data, AI can recommend personalized treatment options, ensuring better results. In a country like India, where there is a large population with diverse medical needs, AI's role in healthcare transformation is undeniable. The financial sector in India is also experiencing significant changes due to the integration of AI technologies. Financial institutions are leveraging AI to streamline operations, enhance customer experience, and improve decision-making processes. AI-powered tools enable banks and insurance companies to automate repetitive tasks, reduce human error, and make more accurate predictions regarding credit risk and investment strategies. Source: tech.einnews #healthcarestartup #AI #healthtech

Soaring healthcare costs in India are pushing even insured individuals to forgo essential treatments and doctor visits, according to a new report by smart preventive healthcare firm GOQii. The “India Fit Report 2025”, based on data from 6 million users and a survey of 2,000 people, paints a grim picture of an emerging health emergency driven by unaffordable care. The report warns that healthcare in India is becoming a luxury, not a necessity. Nearly one in five respondents admitted to skipping essential treatments due to financial constraints, while a staggering 71% said healthcare costs have skyrocketed. Even among those with medical insurance, 36% said they had reduced doctor visits because of the high out-of-pocket expenses. SOURCE- Financial Express #HealthcareCrisis #AffordableHealthcare #IndiaHealthCrisis #RisingMedicalCosts #HealthInsuranceGap #SkipTreatment #HealthcareInIndia #MedicalCostsSkyrocketing #HealthEquity #InsuredButUncovered #HealthcareForAll #IndiaHealthcare

Out of the more than 70 maternal deaths reported between April 2024 and March 2025, delay 1 has been found in 45 cases; delay 2 in 24 cases. The maternal death audit committee of the Pune Municipal Corporation (PMC) has reported over 70 maternal deaths between April 2024 and March 2025, raising serious concerns about access to timely healthcare for pregnant women in the city. As per the report, 22 out of the more than 70 maternal deaths are linked to delay 1 which refers to a delay in the decision to seek medical care and includes delays caused by the lack of awareness, hesitation, or social and financial factors that prevent timely access to healthcare, officials said. Furthermore, in 42 out of the more than 70 maternal deaths, the committee has been unable to determine the type or stage of delay that led to the death pointing to gaps in documentation, investigation, or follow-up in maternal death audits, officials said. According to PMC officials, maternal deaths are often classified using the ‘three delays’ model comprising delay 1 or delay in seeking care; delay 2 or delay in reaching a health facility; and delay 3 or delay in receiving appropriate care at the facility. In some cases, a specific question or data point in the audit form may not be relevant to the circumstances of the maternal death being reviewed. For example, if the death occurred at home, the question about the type of facility where the delivery took place is ‘non applicable’, officials said. SOURCE- Hindustan Times #MaternalHealth #HealthcareAccess #SafeMotherhood #WomensHealth #MaternalMortality #PregnancyCare #SaveMothers #HealthcareForAll #TimelyCareMatters #PublicHealthCrisis

Blue Jet Healthcare, a midcap in the Medical Equipment sector, faced a decline on April 9, 2025, underperforming its sector. However, the stock has shown strong long-term growth, with a significant increase over the past year and a positive year-to-date performance, despite broader market challenges. Short-Term Headwinds In recent weeks, Blue Jet’s stock has dipped due to several short-term factors, including tightening regulatory frameworks, increased raw material costs, and overall market correction across healthcare equities. Quarterly earnings came in slightly below expectations, further fueling a minor sell-off. Long-Term Outlook Remains Positive Despite the current dip, the company’s fundamentals remain robust. Blue Jet Healthcare is deeply involved in the high-growth areas of active pharmaceutical ingredients (APIs), contract manufacturing, and specialty chemicals — sectors expected to expand rapidly over the next decade. The company’s R&D pipeline, global partnerships, and consistent reinvestment in technology position it strongly for long-term expansion. SOURCE- MarketsMojo #BlueJetHealthcare #StockMarket #HealthcareStocks #PharmaIndustry #LongTermInvesting #MarketUpdate #HealthcareInnovation #PharmaNews #InvestmentOpportunity #StockAnalysis

India’s healthcare expenditure is expected to surge from 3.3 per cent to 5 per cent of the country’s GDP by 2030, according to a report by credit ratings company CareEdge out on Monday. Currently, global healthcare spending stands at $10 trillion, about 10 per cent of the world’s GDP, with developed nations like the US, Germany, and Japan incurring relatively high per capita spending. In contrast, developing countries allocate a smaller portion of their GDP to healthcare. For example, India currently spends 3.3% of its GDP on healthcare (as of 2022), which is below the average of 5.1% for developing countries. Higher public spending, along with increased private investments in the healthcare sector, insurance expansion, policy support, and demographic shifts, are driving a structural change. Additionally, India's per capita healthcare expenditure is $80, significantly lower than the sample average of $354 for developing nations. This underinvestment has resulted in inadequate healthcare infrastructure and services, stated the report. However, constraints in rural healthcare infrastructure and the availability of a trained workforce remain critical challenges in expanding coverage. Source- Deccan Herald #EquitableHealthcare #HealthcareForAll #HealthPolicy #InclusiveGrowth #PublicHealthMatters #HealthEconomy #UniversalHealthcare #GDPGrowth #HealthcareReform #HealthyNationWealthyNation

Inspired Spine, a US healthcare organization specialized in spine health and surgery, has developed SURI (Smart Universal Resource Identifier), an AI system that converts multilingual speech into structured medical reports. The Inspired Spine researchers explained that traditional electronic health record (EHR) systems require manual input, contributing to physician burnout and increasing the risk of errors. Existing solutions, such as dictation tools and scribes, offer partial relief but remain costly and inconsistent — especially for providers who speak languages other than English or major European languages. According to them, “SURI enters this landscape as a transformative solution.” It combines automatic speech recognition (ASR) and large language models (LLMs) to generate detailed clinical documentation from doctor-patient dialogues in 21 languages. Source-Slator #HealthcareInnovation #SpeechToText #MedicalTech #MultilingualAI #HealthcareIT #MedicalReports #AIinHealthcare #TechForGood #HealthTech #DigitalHealth #MedicalAI #DataDrivenHealthcare #VoiceRecognition #HealthcareAutomation

​In a strategic move to enhance international career opportunities for Indian healthcare professionals, BorderPlus, co-founded by Mayank Kumar and Ayush Mathur, has acquired Onea Care, a German healthcare recruitment firm. This acquisition marks BorderPlus' first international expansion and underscores its commitment to scaling operations in Europe and beyond. ​ The Bengaluru-based startup has allocated $10 million for mergers and acquisitions, aiming to strengthen its presence in Germany, India, and other markets with a growing demand for qualified healthcare professionals. The company plans to introduce digital-first solutions to streamline hiring processes, enhance language training, and ensure seamless integration for healthcare workers. ​ Mayank Kumar and Ayush Mathur, co-founders of BorderPlus, stated, "This acquisition is a major step toward ensuring that Indian nurses and healthcare professionals have access to structured, fair, and high-quality job opportunities in Germany." ​ Germany is currently facing a significant shortage of nursing staff, with a projected need for 150,000 additional nurses by 2025 and 500,000 by 2030. Onea Care, founded by Leon Bauer, specializes in recruiting nurses from non-EU countries and has established partnerships with hospitals, universities, and care networks across Germany. Bauer will continue in a leadership role, emphasizing that the acquisition combines Onea Care's commitment to supplying top healthcare talent with BorderPlus' focus on Indian healthcare growth. ​ Indian Startup News BorderPlus is dedicated to enabling Indian professionals to build international careers by providing language training, skill development, visa assistance, and employment opportunities to facilitate smooth transitions into global job markets. ​ #BorderPlus #OneaCare #HealthcareRecruitment #InternationalCareers #IndianProfessionals #GlobalOpportunities #MergersAndAcquisitions #Germany #HealthcareShortage #NursingJobs

AI-driven innovations in health are poised to become more significant in healthcare and fields such as cell and gene therapy, affordable care, and maternal, newborn, and child health (MNCH) are to see significant improvements, according to Taslimarif Saiyed, Director and CEO, Centre for Cellular and Molecular Platforms (C-CAMP). According to the Ministry of Ayush, GOI, 2025, the Indian healthcare sector is expected to reach USD 638 billion from USD 110 billion in 2016 due to rising income levels, greater health awareness, increased precedence of lifestyle diseases, and improved access to insurance, which would be the key contributors to growth. C-CAMP has received tremendous support from the government to spur innovations over the years, said Saiyed, and he added that bodies such as the Department of Biotechnology, Niti Ayog, BioBank, the Karnataka Government, and the Centre have been backers of the project. "The support is largely allowing us to build and take, I would say, take risk with such ideas. There's a lot of risk involved because there are new ideas. So we take the role of practitioners on the ground and get resources from the government to identify the talent, attract them, and then hand-hold them for many years till they become successful like that. So that's why the support from the government is very important because when a market doesn't take risk, the government has to take the risk. That's the role of government, and it has been able to to do it," Saiyed told Entrepreneur India. Startup innovations, especially in the healthcare sector has seen significant growth, with healthtech startups reportedly raking in USD 7.25 billion in funding between 2014 and 2024 according to an Inc42 Funding Report. C-CAMP today hosted and mediated a bilateral discussion between the Karnataka Government represented by Dinesh Gundu Rao, Minister of Health and Family Welfare, and Barbara Goezinne, Dutch Vice Minister of Health, Curative Care. Discussions took place around a possible Indo-Dutch partnership to focus on digital health and AI-powered healthtech from the state. "Innovation should be translated into real-world applications and C-CAMP has been playing a crucial role. Several innovations from C-CAMP have already been implemented, such as solutions for eye care and retinopathy treatment. Another example is technology to measure fetal heart rate in the womb. It is great to have visitors from the Netherlands here today—we can learn from experiences and explore potential collaborations in the future," said Gundu Rao. During the meeting, the Dutch delegation expressed interest in finding paths to develop selected advanced Karnataka-based healthcare technology in the Netherlands around scopes such as labor-saving technologies in healthcare, innovations in pharmaceuticals with AI in drug development and discovery, and remote monitoring and telehealth-related solutions as a screening method. Barbara Goezinne said, "The philosophy to make innovative technologies, like stem cell therapy, more accessible and affordable is really inspiring. We are committed to working together in the field of medical technology, particularly in the development of innovative, labour-saving medical solutions to support all health care professionals." C-CAMP's existing portfolio includes more than 80 deeptech startups covering areas such as Artificial Intelligence (AI) and Machine Learning (ML), genomic data analysis, healthcare analytics/big data, computer-assisted diagnosis, Internet of Things (IoT), Virtual & Augmented Reality, wearables, and other similar technologies "We have a strong cohort of AI-based health tech startups that have impact potential not only for resource-poor settings but also the Global North where resources are aplenty but healthcare challenges and economic burden of health persist," added Saiyed. Source: Entrepreneur India #healthcarestartup #dseidehealthcarenetwork

A government official said more than 1,300 staffers were removed from service as they did not resume work despite repeated notices. The Gujarat government has sacked over 1,300 healthcare workers across the state as their indefinite strike to seek better salary continued on Thursday. Maintenance Act against the healthcare staffers posted across the state to demand better pay scales, inclusion in technical cadres, and the cancellation of departmental examinations. A government official said about 11,000 healthcare workers participated in the strike and were issued show-cause notices. “More than 1,300 have been removed from service as they did not resume work despite repeated notices,” the official said, adding that only 5,000 workers were still on strike, “The government is considering all possible options to reach an amicable solution,” the official added. Health minister Rushikesh Patel told reporters that the government will hold talks to find a solution only after the strike is called off. “Not before that,” he said. Source- Hindustantimes #HealthcareCrisis #GandhinagarProtest #HealthcareWorkers #StrikeAction #JobLoss #HealthcareRights #SupportHealthcareWorkers #JusticeForWorkers #WorkersRights #IndiaNews #GujaratNews #HealthcareIndustry

Healthcare startups are set for increased mergers and acquisitions in 2025, driven by cash-strapped firms, declining revenue multiples, and investor caution, particularly in diagnostics and care delivery. Healthcare startups are poised for increased mergers and acquisitions (M&A) in the current calendar year as revenue multiples decline and cash-strapped firms struggle in a tight funding market, according to early-stage healthcare-focused investment firm W Health Ventures. The consolidation wave is expected to be most pronounced in diagnostics, where large pathology chains are likely to acquire smaller, hyperlocal labs and radiology centres to expand their geographic reach. Care delivery companies specialising in single fields such as IVF, eyecare, and oncology may also see exits, with promoters selling to private equity-backed platforms, said Namit Chugh, principal at W Health Ventures. SOURCE-Financial express #HealthcareStartups #MergersAndAcquisitions #HealthTech #StartupFunding #VentureCapital #DigitalHealth #MedTech #HealthInnovation #HealthcareInvestment #HealthTechM&A #StartupGrowth #HealthcareTrends #FundingWinter #HealthTechStartups #HealthcareEcosystem

New Delhi: Care.fi, a pioneering healthcare-focused fintech startup, has secured INR 7.5 Cr in debt capital from Vivriti Capital to accelerate its mission of revolutionizing Revenue Cycle Management (RCM) for hospitals. With a strong emphasis on claims processing and financial automation, this funding will further expand the reach of RevNow by Care.fi, India’s most advanced AI-powered RCM platform designed to optimize hospital insurance claims and streamline revenue realization. This latest investment follows Care.fi’s previous funding rounds, which included INR 8 Cr in debt capital raised from Wint Wealth (Ambium Finserve) and Caspian, along with $2.5 Mn (around INR 21 Cr) in debt from Trifecta Capital and UC Inclusive Credit. In total, the group has raised approximately INR 29 Cr to date. In India’s evolving healthcare ecosystem, managing insurance claims remains a complex challenge for hospitals, often leading to delayed discharges, revenue leakages, and operational inefficiencies. Care.fi has revolutionized hospital claims processing, handling over INR 800 Cr in claims across 300+ hospitals and auditing more than 50,000 claims. Its AI-driven RCM platform, RevNow, is making a significant impact by expediting claim settlements and ensuring hospitals receive payments within 3-5 days post-discharge. It enables 30-minute patient discharges by automating final billing and approvals, drastically reducing wait times. RevNow optimizes hospital workflows with real-time query notifications, automated responses, and integrated mailing services. It also enhances financial transparency by providing real-time reconciliation of cash flows at the entity, unit, and claim levels, offering hospitals unparalleled visibility. Sidak Singh, co-founder of Care.fi, shared, “Since our inception, we have focused on solving critical operational pain points in hospital revenue management. With RevNow, we are setting new benchmarks in claims processing efficiency. This latest funding will enable us to scale further, helping hospitals optimize financial workflows while ensuring better patient experiences. As the healthcare ecosystem grows, we aim to continue innovating and improving revenue realization for providers.” With its latest funding round, Care.fi aims to expand RevNow’s capabilities and integrate further with hospital information systems (HIS), electronic health records (EHR), and billing platforms. The company is also focused on talent acquisition to strengthen its team and further drive innovation in RCM. “Our primary focus is to enhance the reach and effectiveness of our claims processing solutions,” said Vikrant Agrawal, co-founder of Care.fi. “We have already facilitated insurance claims for over 50,000 patients, and this funding will enable us to further expand our presence in the healthcare sector, bringing more hospitals into the fold and improving financial efficiency across the industry.” With an ambitious vision to become a 10 Billion Dollar enterprise by 2030, Care.fi is redefining healthcare finance by bridging gaps in insurance claims processing, ensuring financial stability for hospitals, and enhancing the overall patient experience. Source: APN NEWS #healthcarestartupindia #dseidehealthcarenetwork

​Navina, an AI-powered clinical intelligence platform, has successfully secured $55 million in a Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with participation from existing investors Vertex Ventures Israel, Grove Ventures, and ALIVE. This latest investment brings Navina's total funding to $100 million. ​ Founded in 2018, Navina integrates artificial intelligence with electronic health record (EHR) systems to provide clinical insights, flag potential diagnoses, identify risk factors, and detect medication conflicts. The platform is currently utilized by over 1,300 clinics in the United States, aiming to enhance care quality and patient outcomes by efficiently managing and analyzing patient data. ​ The newly acquired funds will be used to accelerate Navina's expansion across the U.S. healthcare market, enhance its proprietary AI technology, and further drive improvements in patient outcomes by bringing proactive clinical intelligence to every outpatient interaction. ​ Navina plans to use the new funding to enhance its offerings, including developing ambient scribing capabilities for full documentation support. While not yet profitable, CEO Ronen Lavi aims for profitability within the next two to three years. ​ Navina's competitive edge lies in its alignment with clinics' financial needs and a strong provider experience, setting it apart in a competitive market of AI in healthcare data analysis. Source: TechinAsia #healthcarestartupindia #dseidehealthcarenetwork

Since its emergence on the life sciences stage, some of the best use cases of artificial intelligence (AI) have been the creation of indispensable tools for drug discovery, patient engagement, and healthcare operations. However, the biggest opportunity for AI right now is to develop treatments for rare diseases that still have no effective therapies. Shikha Singhal, principal of data science at Axtria, discussed the AI-driven future of the life sciences industry with AIM. “With less than 5% of 7,000 known genetic diseases having treatments, pharma companies will prioritise niche therapies, supported by AI-enabled patient analytics and real-world data,” she said. In 2024, Demis Hassabis and John M. Jumper were awarded the Nobel Prize in Chemistry for their contributions to AI-assisted protein structure prediction. Shikha believes these advancements set the stage for 2025, which promises even greater strides in efficiency and effectiveness, patient engagement, and innovative therapies. As the industry builds on this momentum, Shikha outlined several key trends that will enhance drug lifecycle management. “AI is centre stage right now and pharma is figuring out the ideal human-AI combination, reinventing their business functions with new ways of working,” shikha said. She added that AI and advanced analytics are key to developing tailored medicine, AI-powered cloud solutions enable instant data-driven decisions, and how highly personalised treatments are a reality thanks to the use of digital twins. Shikha says Axtria is leading the charge with AI-based products and services that make digital transformations successful, paving the way for these exciting treatment innovations. Source: analyticsindiamag #healthcarestartupindia #dseidehealthcarenetwork

​After decades of persistent advocacy and struggle, Mumbai's Mankhurd area is set to receive a 410-bed multi-speciality hospital in Lallubhai Compound, a significant development for a community that has long been deprived of adequate healthcare facilities. ​ Lallubhai Compound houses over 45,000 residents, many of whom were relocated from various parts of Mumbai in the early 2000s due to infrastructure projects. Despite this substantial population, the area has historically lacked essential amenities, particularly in healthcare. A 2018 study by Doctors for You revealed that 8-10% of households in the vicinity had at least one member suffering from tuberculosis, underscoring the pressing need for medical services. ​ The new hospital, constructed by the Mumbai Metropolitan Region Development Authority (MMRDA), comprises two ground-plus-nine-floor buildings and an eight-story staff quarters. The facility is slated to be handed over to the Brihanmumbai Municipal Corporation (BMC) in September, nearly a decade after its initial proposal. Currently, the buildings remain unoccupied as the BMC has recently floated a tender inviting bids to operate the hospital under a public-private partnership model. The deadline for bid submission is March 27, after which it will take a few months to commence outpatient services and approximately a year to begin surgical operations. ​ Residents have long faced challenges due to the absence of nearby quality healthcare facilities. The closest option, Shatabdi Hospital in Shivaji Nagar, is often bypassed in favor of Rajawadi Hospital, located 5 kilometers away, or other city hospitals perceived to offer better care. This situation has led to delays in treatment and additional hardships for patients and their families. ​ The establishment of this hospital is the culmination of years of persistent efforts by the community, who engaged with local corporators, Members of the Legislative Assembly (MLAs), and Members of Parliament (MPs) to advocate for improved civic amenities, with healthcare being a primary focus. The realization of this project marks a significant milestone in addressing the healthcare needs of Mankhurd's residents and exemplifies the impact of sustained community activism. Source: The Times of India #healthcarestartup #dseidehealthcarenetwork

NSW Health has been on a transformational journey to modernise and streamline its technology systems. The NSW Ministry of Health has a role of ‘system manager’ to the NSW public health system. More than 228 hospitals across New South Wales, faced fragmented data, inefficiencies in patient flow and care coordination, thus requiring a platform where data from numerous sources could be curated and consolidated in real time. Creating a state-wide Operational Data Store (ODS) supported a platform that provides visibility across a patient’s journey in an environment with multiple Patient Administration Systems and electronic medical records. This ODS was made viable by transitioning NSW Health’s legacy infrastructure to Microsoft Azure, allowing the department to leverage the scalability, security and advanced analytics capabilities offered by the cloud. “The shift to the cloud has been crucial in addressing key pain points, including enhanced resource allocation, improved patient care coordination and a reduction in the reliance on manual, paper-based processes,” said Pedram Bidhendi, Director of System Performance Support at NSW Health. Today, the ODS serves as a real-time operational and analytics platform. The store integrates data from numerous sources across the health system to support a seamless flow of information. By realising its ODS vision and working with Microsoft technologies, NSW Health has modernised its operations and set the stage for ongoing innovation in healthcare delivery. This progress will ensure better outcomes for patients across the state. The latest Australian Institute of Health and Welfare (AIHW) report shows NSW is the best performing jurisdiction for emergency department patients seen on time (74%) and patients receiving planned surgery within clinically recommended timeframes (85.3%). NSW continues to deliver safe, high-quality care. Source- News.microsoft #HealthcareTech #DigitalHealth #NSWHealth #HealthIT #DataDrivenHealthcare #MicrosoftHealth #OperationalDataStore #HealthInnovation #HealthcareWorkers #FutureOfHealthcare #EHR #HealthData #TechForGood #MedicalTechnology #HealthcareTransformation

In a landmark achievement for India's biotech sector and cancer treatment, Delhi-based startup Cellogen Therapeutics has received regulatory approval for the world’s first indigenous Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cells. This breakthrough places India at the forefront of advanced cell and gene therapies, offering new hope for patients battling blood cancers. India ranks third globally in cancer incidence, after the United States and China, with blood cancers accounting for 8 per cent of all newly diagnosed cases. According to the GLOBOCAN report, leukaemia, lymphoma, and multiple myeloma affect thousands of patients in India, including around 30,000 children annually. Cellogen Therapeutics’ bi-specific CAR T platform represents a transformative advancement in cancer immunotherapy. Unlike conventional CAR T therapies that target a single antigen, this innovation engages two tumour-specific antigens simultaneously, improving treatment precision while reducing side effects such as cytokine release syndrome and neurotoxicity. "This approval is a testament to India’s growing expertise in cutting-edge biotechnology and precision medicine," said Dr. Gaurav Kharya, founder of Cellogen Therapeutics. “Developing this CAR T product required three years of relentless research. Our goal has always been to create world-class therapies that are both accessible and affordable, and this innovation brings us closer to that vision.” This development aligns with the Atmanirbhar Bharat (self-reliant India) initiative, reinforcing India’s ability to drive medical innovation. CAR T therapy has traditionally been dominated by Western countries, with treatment costs exceeding USD 400,000. However, Cellogen’s technology is expected to reduce these costs by over 90 per cent, making life-saving therapies more accessible, especially in low- and middle-income countries. Cellogen Therapeutics has received $2 million in funding from NATCO Pharma, which has acquired a 5.38 per cent stake in the company. The startup is set to begin clinical trials in collaboration with Christian Medical College (CMC), Vellore, evaluating the safety and efficacy of the therapy. Dr. Tanveer Ahmad, lead researcher and CAR T cell therapy expert emphasised the impact of this innovation, “Our Bi-Specific 3rd Generation CAR T platform is the result of years of rigorous research and state-of-the-art cell engineering. This therapy offers a highly targeted and durable treatment option, significantly improving patient outcomes.” The research is backed by leading institutions, including the Council of Scientific & Industrial Research (CSIR), the Regional Centre for Biotechnology, the Institute of Genomics and Integrative Biology, and NATCO Pharma. With this approval, Cellogen Therapeutics is set to redefine cancer treatment, making CAR T therapy more effective, affordable, and accessible for Indian and global patients. Source: Healthcare World #healthcarestartupindia #dseidehealthcarenetwork

Bill Gates, the former Microsoft CEO and co-chair of the Bill & Melinda Gates Foundation, is in India where he discussed significant advancements in healthcare and tech. For all the latest world news, analysis and updates, NDTV's 'The World 24X7' with Parmeshwar Bawa is your one-stop shop. ​Bill Gates, co-chair of the Bill & Melinda Gates Foundation and former CEO of Microsoft, is currently visiting India to engage with leaders and innovators on the nation's advancements in healthcare and technology. On March 19, 2025, he delivered a keynote address at 'Future Forward,' a global forum hosted by the Confederation of Indian Industry (CII) in collaboration with the Gates Foundation and the Women’s Collective Forum, held at the Pradhan Mantri Sangrahalaya in New Delhi.​ In his speech, Gates lauded India's role as a global leader in innovation, particularly highlighting the country's progress in affordable healthcare, AI-driven diagnostics, and digital public infrastructure. He emphasized that India's solutions have the potential to transform global health and development, stating, "India is not just building for itself; it is creating solutions that have the potential to transform global health and development." He also praised India's rapid advancements in digital ecosystems, inclusive economic growth, and technological breakthroughs, calling them a model for the world. ​ Gates acknowledged India's significant progress in health and development through low-cost innovations. He noted that the country's pioneering role in affordable healthcare, AI-powered diagnostics, and digital public infrastructure is building the future. He reinforced the importance of scaling India's innovative solutions globally to address pressing challenges in emerging economies. ​ During his visit, Gates met with Prime Minister Narendra Modi, expressing his admiration for how India's innovation is driving progress both locally and globally. They discussed various subjects, including technology, innovation, and sustainability. Gates also met with Union Health Minister J.P. Nadda to review the collaboration between the Indian government and the Gates Foundation in the healthcare sector, covering key areas such as maternal health, immunization, and sanitation. ​ Gates highlighted India's advancements in digital public infrastructure, including initiatives like Aadhaar and digital payment systems, which have improved access to banking, healthcare, and government services. He mentioned that India is using AI-powered tools to enhance early disease detection, improve pregnancy care, and manage patient data more effectively. ​ Overall, Gates's visit underscores India's growing influence in global health and development, with its innovative solutions serving as models for other countries to emulate.​ Source- NDTV .com #BillGates #IndiaInnovation #DigitalIndia #HealthcareAdvancement #AIinHealthcare #TechForGood #HealthcareInnovation #AIinMedicine #DigitalHealth #GlobalHealth #HealthTech

Zeno Health has launched a 50-minute medicine delivery service in India after raising US$25 million in its series C funding round. The healthtech startup operates over 180 retail pharmacy stores across Maharashtra, India, integrated with a tech-enabled logistics network. Customers can order medicines via its mobile app, in-store, or by phone, with no minimum order or delivery fee. Founded in 2017, Zeno Health focuses on affordable generic medicines by sourcing directly from manufacturers. It also runs 200 micro-franchises in Maharashtra and West Bengal, serving over 1.5 million customers. The company has raised over US$56 million from investors like STIC Investments and Lightbox, aiming to expand operations and enhance its technology. The 50-minute delivery service taps into the growing demand for rapid healthcare delivery. Competitors like Tata 1mg, Netmeds, PharmEasy, and Flipkart Health+ are active in this space. New players such as Plazza and quick commerce platforms like Flipkart Minutes and Swiggy Instamart are also exploring opportunities. Source: TechInAsia #healthcarestartupindia #dseidehealthcarenetwork

Sarvam AI, founded in 2023 by Dr. Vivek Raghavan and Dr. Pratyush Kumar, is a Bengaluru-based startup pioneering India's first homegrown generative AI tailored for the country's diverse linguistic landscape. The company focuses on developing large language models (LLMs) that support multiple Indian languages, aiming to make AI accessible and practical for all. In December 2023, Sarvam AI secured a $41 million Series A funding round led by Lightspeed, with participation from Peak XV Partners and Khosla Ventures. This investment underscores the company's potential to create AI applications at a population scale, specifically designed for India's multilingual environment. By October 2024, Sarvam AI launched Sarvam-1, a homegrown LLM with approximately two billion parameters, supporting 10 major Indian languages, including Bengali, Marathi, Tamil, and Telugu. Built using NVIDIA's H100 Tensor Core GPUs, Sarvam-1 claims to outperform standard benchmarks while achieving high accuracy in both knowledge and reasoning tasks, particularly in Indic languages. In February 2024, Sarvam AI collaborated with Microsoft to make its Indic voice LLM available on Azure. This partnership leverages Azure's AI infrastructure to build and deploy voice-enabled generative AI applications, aiming to empower enterprises to adopt AI solutions quickly and responsibly. Sarvam AI's commitment to advancing AI adoption in India is further demonstrated by its development of Sarvam 1, a 2-billion-parameter multilingual LLM supporting 11 languages: Bengali, Gujarati, Hindi, Marathi, Malayalam, Kannada, Oriya, Tamil, Telugu, Punjabi, and English. Built entirely on NVIDIA technology, Sarvam 1 is designed to power a range of applications, including voice and messaging agents, and is available as an open-source model for developers to build their own generative AI applications for Indic language speakers. Through these initiatives, Sarvam AI is positioning itself as a leader in developing AI solutions that cater to India's unique linguistic and cultural diversity, contributing significantly to the country's AI ecosystem. India Is Emerging as a Key Player in the Global AI Race Source: Business Today #healthcarestartup #AI #dseidehealthcarenetwork

IM Kashipur and Max Healthcare launch the second batch of their executive hospital management programme, doubling intake to meet growing industry demand. The Indian Institute of Management (IIM) Kashipur, in association with Max Healthcare, has introduced the second batch of its Post Graduate Executive Programme in Hospital Management, which will commence on March 28, 2025. The batch size has been doubled this year, reflecting the growing demand for specialist healthcare management education. To meet industry requirements, new topics like Digital Transformation, Research Methodology, Entrepreneurship, Hospital Planning and Design, and an Industry-Specific Masterclass have been added by IIM Kashipur. These new topics support integral topics like Healthcare Economics, Strategic Management, Medico-Legal Studies, and Financial Management. Prof. Kunal Ganguly, Dean (Development), IIM Kashipur, observed the programme's accelerated growth and commented, "The increasing demand for professional health care management education reflects its worth in gearing up leaders to combat new challenges and fuel innovation in the field." The programme adopts a hybrid learning approach with live online sessions, on-campus exposure, hospital contact hours, and actual case studies. One of the major attractions is the Capstone Project, providing experience in solving hospital management problems. Tailored to healthcare professionals, budding entrepreneurs, and career changers entering the healthcare leadership arena, the programme offers networking benefits and certification by IIM Kashipur and Max Healthcare. Source- India Today #IIMKashipur #MaxHealthcare #HospitalManagement #HealthcareLeadership #PGExec #HealthcareEducation #ExecutiveProgram #HealthcareManagement #ProfessionalGrowth #LeadershipDevelopment #HealthcareInnovation

Founded in 2024 by Harshit Kukreja and Akash Kumar, Raaz offers personalised, evidence-based male reproductive treatment for conditions like erectile dysfunction and premature ejaculation. Men’s reproductive health remains a largely taboo subject in India, with millions suffering in silence from conditions such as erectile dysfunction, premature ejaculation, testosterone deficiency, and sperm count issues. While conversations around women’s health have gained momentum, male reproductive health continues to be overlooked, leaving many without access to proper diagnosis or treatment. According to the Indian Society for Assisted Reproduction, nearly 15% of Indian couples face infertility issues, with male factors contributing to almost 50% of cases. A study by the Indian Journal of Urology further reveals that nearly one in four men experience sexual dysfunction, yet only a small fraction seek professional help due to stigma and misinformation. Addressing this gap, Raaz, a Delhi-based startup, offers discreet, accessible, and medically backed solutions for male reproductive health. Source: Your Story #healthcarestartupindia #startupfunding #dseidehealthcarenetwork

The International Finance Corporation (IFC), a member of the World Bank Group, has proposed an equity investment of up to $35 million, with an additional co-investment envelope of up to $30 million, into A91 Partners' third fund. This new fund aims to raise $675 million in total commitments, marking A91's largest fund to date. A91 Partners, established in 2018, focuses on providing capital to small and mid-market companies across sectors such as consumer, financial services, healthcare, manufacturing, and technology. The third fund is expected to invest between $10 million to $50 million in approximately 15 companies. The firm has shown significant growth in its fundraising efforts: First fund (2018): $350 million Second fund: $550 million Third fund (current target): $675 million A91's investment portfolio includes companies like Akshayakalpa (dairy products), Blue Tokai (specialty coffee), and Sugar (beauty and personal care). Additionally, their portfolio company, Go Digit General Insurance, went public last year. This proposed investment by IFC reflects a growing interest in Indian venture capital firms, with others like Accel and Bessemer Venture Partners also raising substantial India-focused funds recently. Source: Your Story #healthcarefundingindia #dseidehealthcarenetwork

India is taking a major step towards pharmaceutical innovation by launching a ₹5,000 crore Research & Development (R&D) fund to boost drug discovery and medical research. The initiative aims to position India as a global leader in pharmaceuticals by encouraging research in novel drug formulations, biologics, and cutting-edge healthcare technologies. The fund will provide financial support to pharmaceutical companies, startups, and research institutions, fostering innovation in critical areas such as oncology, rare diseases, and precision medicine. This move aligns with the government's vision of strengthening the "Make in India" and "Atmanirbhar Bharat" initiatives, reducing dependency on imports and enhancing self-sufficiency in life-saving drugs. With India's pharma sector projected to reach $130 billion by 2030, this investment in R&D is expected to drive groundbreaking advancements, attract global collaborations, and create new job opportunities. Experts believe that with increased funding, India can bridge the gap between generic drug production and high-end pharmaceutical innovation, further solidifying its position as the "Pharmacy of the World." This strategic push for innovation marks a transformative era for India's pharmaceutical and healthcare ecosystem. #PharmaInnovation #MakeInIndia #AtmanirbharBharat #HealthcareResearch #BiotechIndia #MedTech #PharmaR&D #DrugDiscovery #HealthcareInnovation #Dseidehealthcarenetwork Source: IndiaMed Today

​The Mizoram government is set to launch the Mizoram Universal Healthcare Scheme (MUHCS) on April 1, 2025, providing an annual health coverage of up to ₹5 lakh per family. This initiative aims to offer cashless treatment at state-run hospitals, health facilities (from primary healthcare centers upwards), and empaneled private or church-run hospitals. ​ The MUHCS is designed to be inclusive, covering families across various economic backgrounds, including government employees. It aligns with the Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) concerning benefit coverage, pre-existing conditions, and hospitalization expenses. ​ General Plan: ₹2,500 annual premium per family for treatment in general wards.​ Standard Plan: ₹5,000 annual premium per family for semi-private wards.​ Private Plan: ₹10,000 annual premium per family for private wards.​ Government employees, including contractual and muster-roll staff, will have monthly premiums ranging from ₹200 to ₹1,500. ​ Registration for the scheme is currently open and will continue until May. Offline registration is being managed by officials at various sub-health centers, with online registration set to commence in April. Post-May, registration will reopen in July, subject to a fine. ​ While many private and church-run hospitals, especially in Mizoram's southern regions, have agreed to implement the scheme, negotiations are ongoing with private hospitals in the state capital, Aizawl. ​ The MUHCS represents a significant step toward enhancing healthcare accessibility and affordability for all Mizoram residents.​ taxmanagementindia.com SOURCE- ET HEALTH WORLD #Mizoram #Healthcare #MUHCS #HealthForAll #UniversalHealthcare #AyushmanBharat #HealthcareScheme #MizoramGovt #AffordableHealthcare #CashlessTreatment #PublicHealth #HealthcareAccess #Wellness #HealthCoverage #MedicalCare #HealthInsurance

The Transformative Impact of Artificial Intelligence in Healthcare Artificial Intelligence (AI) is revolutionizing the healthcare industry, bringing innovative solutions to patient care, diagnostics, drug development, and hospital management. The integration of AI in healthcare is not only enhancing efficiency but also improving accuracy and patient outcomes. 1. AI in Diagnostics and Medical Imaging One of the most significant applications of AI in healthcare is in diagnostics and medical imaging. AI-powered tools can analyze medical images, such as X-rays, MRIs, and CT scans, with remarkable accuracy. Deep learning models, particularly convolutional neural networks (CNNs), have demonstrated exceptional performance in detecting diseases like cancer, pneumonia, and retinal disorders. AI-driven diagnostic tools help radiologists identify abnormalities faster, leading to early detection and timely intervention. 2. AI in Drug Discovery and Development AI is accelerating drug discovery by analyzing complex biological data and predicting potential drug candidates. Traditional drug development processes can take years and cost billions of dollars, but AI-driven models can identify promising compounds in a fraction of the time. AI is also playing a crucial role in personalized medicine by analyzing genetic data to predict patient responses to specific treatments, thereby enhancing the efficacy of therapies. 3. AI in Patient Care and Virtual Assistants AI-powered chatbots and virtual assistants are transforming patient engagement by providing instant medical advice, scheduling appointments, and monitoring chronic conditions. These tools can analyze patient symptoms and recommend appropriate actions, reducing the burden on healthcare professionals and ensuring timely interventions. AI-driven wearable devices can also track vital signs and alert doctors in case of any abnormalities. 4. AI in Robotic Surgery Robotic-assisted surgeries, powered by AI, are improving surgical precision and reducing risks. AI enables robotic systems to perform minimally invasive procedures with greater accuracy, leading to shorter recovery times and improved patient outcomes. Surgeons can leverage AI-powered robots for delicate procedures, such as neurosurgery and orthopedic surgery, ensuring higher success rates. 5. AI in Healthcare Administration AI is streamlining administrative tasks in hospitals and healthcare facilities, reducing paperwork and enhancing efficiency. AI-driven systems can automate billing, insurance claims processing, and patient record management, allowing healthcare providers to focus more on patient care. Predictive analytics can also optimize hospital resource allocation by forecasting patient admissions and managing staff schedules effectively. 6. AI in Predictive Analytics and Disease Prevention AI models can analyze vast amounts of healthcare data to predict disease outbreaks and identify at-risk populations. Machine learning algorithms assess electronic health records (EHRs) and lifestyle data to detect early signs of chronic diseases, such as diabetes and cardiovascular disorders. Preventive healthcare powered by AI helps in reducing hospitalizations and improving public health outcomes. Challenges and Ethical Considerations Despite its immense potential, AI in healthcare faces challenges, including data privacy concerns, bias in AI algorithms, and regulatory hurdles. Ensuring transparency and ethical use of AI is crucial to gaining trust among healthcare professionals and patients. Additionally, continuous monitoring and validation of AI models are necessary to ensure their accuracy and reliability. Conclusion Artificial Intelligence is reshaping the future of healthcare, offering advanced solutions for diagnostics, drug discovery, patient care, and hospital management. As AI technology continues to evolve, it has the potential to create a more efficient, accessible, and personalized healthcare system. However, addressing ethical challenges and ensuring responsible AI deployment will be key to maximizing its benefits while minimizing risks. SOURCE- telefonica #AI #Healthcare, #AIinHealthcare #Medtech

Bessemer Venture Partners has raised $350 million for its second dedicated India fund, reaffirming its commitment to supporting India's thriving startup ecosystem. Here's a breakdown of what the new fund means for entrepreneurs: Key Focus Areas of the New Fund AI, SaaS, Fintech, and More: The fund will target early-stage investments across industries like AI-enabled services, SaaS, fintech, digital health, consumer products, and cybersecurity. Supporting Growth: While focused on early-stage startups, Bessemer will also back companies through subsequent growth stages to scale effectively. A Long-Term Commitment to India Bessemer’s presence in India dates back nearly 20 years, during which time the firm has invested in over 80 startups. With this new fund, the firm reaffirms its dedication to partnering with founders early and supporting them long-term. Insights from Bessemer Leadership Vishal Gupta, Partner and Managing Director of Bessemer's Bangalore office emphasized the firm's ongoing focus: “This fund deepens our commitment to India’s startup ecosystem as we continue backing the next generation of entrepreneurs building technology-led businesses.” He added, “We remain focused on identifying and investing in founders who are driving innovation, solving complex challenges, and building market-defining companies. Beyond providing capital, we bring deep sector expertise, a global network, and hands-on support to help founders navigate their growth journeys and scale sustainably.” Anant Vidur Puri, Bessemer Partner, highlighted India's role in the AI revolution: "India is at the forefront of the AI-driven transformation, with founders building domestic as well as globally competitive businesses across enterprise software, fintech, and consumer technology." Bessemer has consistently invested early in key market shifts, including the mobile revolution, India’s digital infrastructure, and the healthcare revolution. Notable investments include Urban Company, Perfios, and Medi Assist. The first India fund also backed successful startups like Boldfit, MoveInSync, and Pepper Content. With a globally integrated team, Bessemer is committed to supporting innovation and fostering the next generation of leaders in India’s digital economy. The new fund positions them well to continue nurturing the future of tech in India. Source: Ciol #healthcarestartupfunding #startupfunding #dseidehealthcarenetwork

Allo Health, a pioneering sexual wellness startup, has secured ₹16 crore in a pre-Series A funding round led by Zerodha's Rainmatter, with participation from existing investors. This investment marks a significant milestone in Allo's mission to revolutionize India's sexual health landscape by expanding its clinic network, enhancing AI-driven treatment protocols, and improving patient engagement. Founded by Pranay Jivrajka, Allo Health operates over 35 clinics across major cities like Bangalore, Mumbai, and Hyderabad, treating over 200,000 patients with an impressive 85% improvement in outcomes. The startup's hybrid model combines physical clinics with AI-powered treatments and expert-led care, addressing the long-standing stigma and accessibility issues in sexual health. Beyond sexual health, Allo plans to expand into mental health, leveraging its structured and patient-first approach. The company aims to invest in diagnostics, digital therapy, and private-label solutions to strengthen its healthcare ecosystem. This funding validates Allo's vision to transform healthcare in India by focusing on patient outcomes and evidence-based care. As Allo continues to grow, it is poised to redefine how sexual and mental health services are delivered across the country. #AlloHealth #SexualHealth #MentalHealth #HealthcareInnovation #Rainmatter #Zerodha #HealthTech #IndiaHealthcare #PatientFirstApproach #HealthcareEcosystem #Dseidehealthcarenetwork Source: APN News

Adult immunization is essential in preventing infectious diseases such as influenza, hepatitis B, pneumococcal infections, and cervical cancer. However, in India, it remains largely neglected due to several factors, including low awareness, lack of structured policies, and the misconception that vaccines are only for children. Unlike childhood immunization, which is well-integrated into public health programs, adult vaccination is not widely promoted. Many healthcare providers do not actively recommend vaccines for adults, leading to a lack of motivation among the general population. Another major barrier is cost. Since most adult vaccines are not covered under government-funded programs, individuals must pay out-of-pocket, making them less accessible. Additionally, cultural beliefs and misinformation contribute to vaccine hesitancy. With an aging population and increasing prevalence of lifestyle diseases, prioritizing adult immunization can significantly reduce healthcare costs, hospitalizations, and mortality rates. Strengthening policies, integrating vaccinations into routine health check-ups, and launching public awareness campaigns can help improve immunization rates among adults in India. #AdultImmunization #VaccinationAwareness #PreventiveHealthcare #PublicHealthIndia #StayProtected #ImmunizationMatters #HealthyIndia #DiseasePrevention #Dseidehealthcarenetwork Source: The Hindu

Brokerage firm Morgan Stanley on Thursday, March 13, projected a 17.5% upside on shares of newly listed Dr. Agarwal's Health Care Ltd. after initiating coverage on the stock. The brokerage has an "overweight" rating on Dr. Agarwal's with a price target of ₹502 per share. This is the first analyst rating the stock has received after its listing last month. Morgan Stanley said India's eyecare industry has a high total addressable market, high barriers to entry and high returns, as it is asset-light. As the segment's leading brand and backed by a doctor-promoter team, Dr. Agarwal's Healthcare appears well-positioned to outperform its peers, the brokerage said. The company's revenue is 1.7 times the level of its closest peer, Morgan Stanley added. Morgan Stanley expects Dr. Agarwal's revenue and Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) to grow at a Compounded Annual Growth Rate (CAGR) of 19% each between financial year 2025 and 2027. Shares of Dr. Agarwal's Health Care Ltd made a sluggish debut on the bourses last month, listing at ₹396.90 against the IPO issue price of ₹402 on the BSE. This reflected a discount of around 1.2% from the issue price. SOURCE- Cnbctv18 #DrAgarwalsHealthcare #IPO #StockMarket #EyeCareIndustry #InvestmentAnalysis

Bengaluru-based health startup Allo Health has raised 16 crore rupee (US$1.83 million) in a pre-series A funding round led by Rainmatter, with participation from existing investors. The funds will be used to expand its clinic network, enhance AI-driven treatment frameworks, and develop patient-focused innovations. Allo Health operates over 35 clinics across India, including in Bangalore, Mumbai, Hyderabad, and Pune. Since its launch, the company has treated more than 200,000 patients. This funding follows a US$4.4 million seed round led by Nexus Venture Partners, with investments from Flipkart co-founder Binny Bansal and Zomato founder Deepinder Goyal. The startup continues to pursue a hybrid healthcare model, combining physical clinics with technology-driven treatment approaches. Source: Tech in Asia #healthtechstartup #startupfunding #dseidehealthcarenetwork

What makes AstraAI Special? Checkout the products released in the market place !

Zydus Lifesciences is set to acquire a significant stake in French medtech company Amplitude for ₹2,446 crore, marking a strategic expansion into the global orthopedic implant market. Amplitude, known for its innovative solutions in joint reconstruction and orthopedic surgery, aligns with Zydus’ vision to strengthen its medical technology portfolio. This acquisition will enhance Zydus’ presence in the European market while leveraging Amplitude’s expertise in high-performance orthopedic devices. The move signifies Zydus’ commitment to advancing healthcare solutions and broadening its footprint beyond pharmaceuticals. With the global orthopedic market growing rapidly, this deal positions Zydus as a key player in medtech innovation. The acquisition is expected to drive synergies between both companies, fostering research and development in next-gen orthopedic solutions. #Zydus #Amplitude #MedTech #HealthcareInnovation #Orthopedics #MedicalDevices #HealthcareExpansion #GlobalHealthcare #ZydusLifesciences #HealthcareTech #Dseidehealthcarenetwork Source: The Economic Times